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ABSTRACT
Background
The QuantiFERON In-Tube (QFT IT) assay is an Interferon-gamma release assay
(IGRA) which is currently used to detect Mycobacterium tuberculosis (M. tb) infection. It
however cannot differentiate between latent infection and active tuberculosis (TB)
disease. In an attempt to improve this tool to accurately diagnose active TB, the release
of a variety of markers should be assessed in combination with Interferon gamma (IFN-
γ). Luminex analysis was previously done on QFT plasma and promising candidates
were identified which could be of great value in treatment response studies. IFN-γ
ELISpot, are not only used to detect M.tb infection, but is also implicated in vaccine trails
to assess immunogenicity. The IFN-γ ELISpot and flow cytometry are the most common
assays to assess these phenomena during clinical trials. Our aim therefore was to
develop a multi platform immune analysis assay using the QFT IT system.
Study design and method
The first approach of this study was to optimize the QFT IT assay for flow
cytometry applications. The following questions formed part of the optimization study:
How does the QFT whole blood assay (QFT-WBA) compare to the currently used WBA?
Is antigen re-stimulation required after the initial incubation time and for how long should
cells be re-stimulated in the presence of Brefeldin A? The second approach was to use
the optimized QFT-WBA for community controls (CTRL), household contacts (HHC) and
TB cases, which were recruited from the high TB incidence areas Ravensmead, Uitsig
and Elsies River. The infection status of each participant was determined by IFN-γ
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ELISA and Luminex analysis was performed to measured wide range of cytokine
expression. In addition immune cell markers like CD14, CD4, CD8, CD19, and T cell
receptor gamma delta (TCRγδ) were characterized; polyfunctional characteristics (IFN-γ,
Tumor necrosis factor-alpha (TNF-α) and Interleukin-2 (IL-2)) and proliferation (Ki-67+)
of T cells determined by flow cytometry.
Results
After stimulating the whole blood of the study participants for 22 hours with the M.
tb specific antigens, early secreted antigenic target 6 kDa (ESAT-6), culture filtrate
protein-10 kDa (CFP-10) and TB7.7 the levels of TNF-α producing CD4 T cells were
elevated in TB cases compared to HHCs. After stimulating the whole blood for 6 days
TNF-α producing T cells declined in TB cases and HHC showed a higher expression.
CD40L+CD4+ (p=0.0225) was increased in HHC while IL-9+CD8+ (0.3230) was
decreased in HHC compared to TB cases. Other markers such as IL-5(AG-NIL), IL-13(Ag-
NIL), FGF basicAg, GM-CSFNIL, VEGFNIL/(Ag-NIL), MIP-1βAg and MCP-1Ag/(Ag-NIL) showed
significant differences between HHC and TB cases.
Conclusions
The responses in the QFT-based assay were generally comparable to the WBA
that is routinely used. The differences of TNF-α expression seen in QFT-WBA and QFT-
LPA could be explained by the fact that effector T cell responses were measured in the
short term assay and the central memory T cell responses in the long term assay. Our
study therefore shows that the QFT-based tests can be used to simultaneously assess a
wide range of immunological markers and not only IFN-γ expression.
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Agtergrond
Die QuantiFERON In Tube (QFT IT) toets is ‘n Interferon-gamma vrystellingstoets
(IGRA) wat huidiglik dien as ‘n maatstaf van Mycobacterium tuberculosis (M. tb) infeksie.
Hierdie toets kan egter nie onderskei tussen latente infeksie en aktiewe tuberkulose
(TB) nie. ‘n Noemenswaardige verbetering in die vermoë van hierdie toets om aktiewe
TB te diagnoseer, berus op die studie van ‘n verskeidenheid vrygestelde merkers,
insluitend Interferon gamma (IFN-γ). In vorige Luminex studies op QFT plasma, is
belowende kandidate geïdentifiseer wat van groot waarde kan wees vir studies wat
fokus op die reaksie tot behandeling. Die IFN-γ ELISpot dien nie net as ‘n maatstaf van
M.tb infeksie nie, maar word ook in vaksienproewe betrek om die aard van immuniteit te
ondersoek. Die IFN-γ ELISpot toets sowel as vloeisitometriese toetse, is van die mees
algemene toetse om hierdie verskynsels te meet, tydens kliniese proewe. Die doel van
hierdie studie was dus om die QFT IT sisteem te ontwikkel as ‘n basis vir ‘n multi-
platform immunologiese analiseringstoets.
Studie ontwerp en metode
Die inleidende benadering van hierdie studie was die optimisering van die QFT IT
toets, vir vloeisitometrie doeleindes. Die volgende vrae het deel uitgemaak van die
optimiseringstudie: Hoe vergelyk die QFT heelbloedtoets (QFT-WBA) met huidige WBAs
wat in gebruik is? Word meermalige antigeenstimulasies benodig na die oorspronklike
inkubasieperiode en hoe lank moet die tydperk wees vir sellulêre opvolgstimulasie, in
die teenwoordigheid van Brefeldin A? As ‘n tweede benadering, was om die
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geoptimiseerde QFT-WBA te gebruik vir gemeenskapskontroles (CTRL), huishoudelike
kontakte (HHC) en TB gevalle. Al drie hierdie groepe was opgeneem uit Ravensmead,
Uitsig en Elsies Rivier, areas met betreklik hoë vlakke van TB infeksie. Elke persoon in
die studie se vlak van infeksie is vasgestel met behulp van die IFN-γ ELISA en Luminex
analiese was uitgevoer, om ‘n wye verskeidenheid uitdrukkingsvlakke van sitokiene te
meet. Dies meer, was immuunselmerkers soos CD14, CD4, CD8, CD19 en T sel
reseptor gamma delta (TCRγδ) gekarakteriseer. Meervuldige funskionele karakteristieke
(IFN-γ, Tumor nekrose faktor-alpha (TNF-α) en Interleukin-2 (IL-2)) en
vermenigvuldiging van T-selle, was vasgestel deur middel van vloeisitometrie.
Resultate
Nadat die heelbloed van studiedeelnemers gestimuleers was met M. tb spesifieke
antigene, vroeë afskeidings antigeniese teiken 6kDa (ESAT-6), kultuurfiltraatproteïn
10kDa (CFP-10) en TB7.7, vir 22 uur, was gevind dat vlakke van TNF-α produserende
CD4 T selle hoër was in TB pasïente, in vergelyking met HHCs. Nadat die heelbloed vir
6 dae gestimuleer was, het die vlak van TNF-α produserende T-selle afgeneem in TB
pasïente, terwyl dit hoër was in HCC. CD40L+CD4+ (p=0.0225) het hoër vlakke bereik
in HHC, terwyl IL-9+CD8+ (0.3230) vlakke afgeneem het, in vergelyking met TB
pasïente.  Ander merkers soos,onder andere, IL-5(AG-NIL), IL-13(Ag-NIL), FGF basicAg, GM-
CSFNIL, VEGFNIL/(Ag-NIL), MIP-1βAg and MCP-1Ag/(Ag-NIL), het noemenswaardige verskille
geopenbaar tussen HHC en TB pasïente.
Stellenbosch University http://scholar.sun.ac.za
vii
Gevolgtrekking
Die reaksies waargeneem in die geval van die QFT gebaseerde toets, was in die
algemeen vergelykbaar met dié van die WBA. Die verskille wat waargeneem was vir die
uitdrukkingsvlak van TNF-α in QFT-WBA en QFT-LPA , kan moontlik toegeskryf word
aan die feit dat effektor T-sel reaksies in die korttermyntoets gemeet was, terwyl die
sentrale geheue T-sel reaksie gemeet was in die langtermyntoets. Hierdie studie het dus
gewys dat die QFT gebaseerde toetse gebruik kan word vir die gesamentlike ondersoek
van ‘n wye verskeidenheid immunologiese merkers en nie net vir die uitdrukking van
IFN-γ nie
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CHAPTER ONE – INTRODUCTION
1 CHAPTER ONE - INTRODUCTION
There are two ways to life:
One is the common, direct, and brave.
The other is bad, leading through death, and that is the genius way.
“Magic Mountain” Thomas Mann
Stellenbosch University http://scholar.sun.ac.za
CHAPTER ONE INTRODUCTION
2
1.1 Epidemiology of Tuberculosis
Tuberculosis (TB) has a long history. The disease was first documented 5,000
years ago in Egyptian mummies, which showed pathological signs of tubercular decay in
their spinal column (102). Subsequent discoveries were made in India 3,300 years ago
and in China 2,300 years ago. The prevalence of TB escalated long before colonization
and slavery, spreading in Rome, in Borneo, before any European contact and even in
the American natives before Columbus (58). The outbreak among the American natives
was established only around 1880 when they were forced to live in reservations or
prisons (63;83). In Europe the epidemic started in 17th century and was present for the
next 200 years. Europeans who conquered Africa brought TB into the small villages that
had never been exposed before. Similarly, African slaves taken to America got exposed
to TB and transmitted the disease into their homes upon returning, which resulted in
increasing of TB mortality in the villages (58).
Today one third of the population worldwide is infected with TB. It remains a major
global health problem (26;68;113) and is the leading cause of death in low- and middle-
income countries (60)(Figure 1.1). In 2011, the WHO reported an estimated 8.7 million
incident cases, of which 1.1 million are reportedly co-infected with HIV, and 1.4 million
people died of TB disease. Looking at absolute numbers of TB incident cases in 2010,
South Africa is ranked in third position with 0.4-0.6 million, following India and China.
Africa accounts for the highest number of people co-infected with HIV with 39% of TB
cases co-infected with HIV. This accounts for 79% of the global TB-HIV co-infection
statistics. About 6% of TB cases involve children (114). In an environment where TB
occurs prolifically, infection of children occurs mainly via transmission of M. tb by adults
Stellenbosch University http://scholar.sun.ac.za
CHAPTER ONE INTRODUCTION
3
(61). Predictably, children living in low socio economic settings are at even higher risk of
infection due to increased transmission in crowded living conditions (25).
Figure 1.1: Estimated incident rate of tuberculosis worldwide. (WHO 2012)
1.2 Pathogenesis of Mycobacterium tuberculosis (M. tb)
1.2.1 M. tb: Causative agent of TB
M. tb, which causes TB, is a slow growing acid-fast bacterium with about a 12 hour
replication time, while most of other bacteria only need 30min (47;102). M. tb is a rod-
shaped bacterium approximately 0.3-0.6µm in width and 1.0µm in height (24) (Figure
1.2). The resistant and unique cell wall, composed of the covalently attached glycolipids,
arabinogalactans, peptidoglycans and other free lipids and protein molecules, allows the
bacterium to survive inside the macrophage, without getting phagocytosed (24).
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Figure 1.2: Phagocytosis of Mycobacterium tuberculosis. Colored scanning electron
micrograph of a white blood cell (orange) engulfing bacteria (blue rods). (Credit: Dr Kari
Lounatmaa / Science Photo Library. http://www.nobelprize.org)
1.2.2 Tuberculosis infection in humans
Pattern of TB
TB infection typically occurs during childhood upon first exposure to tubercle bacilli,
hence the description of childhood TB or primary TB. Although M. tb infections has been
associated with erythema nodosum and fever, the initial exposure to M. tb is usually
asymptomatic (109). If the infection does not lead to disease, it can enter a latent stage
of infection. Post-primary TB refers to reactivation of latent bacilli, while TB disease due
to re-infection is described as secondary TB (40). Post primary TB can either affect the
lungs (pulmonary TB) or other body parts such as the spine, joints, genitourinary tract,
nervous system or abdomen (extra-pulmonary TB) (72).
Progression of TB
TB is a chronic infection with tubercular bacilli, which get transmitted through
coughing, sneezing or singing by a patient with active disease. Following inhalation, the
bacilli are inoculated into the respiratory bronchioles and alveoli. In immunocompetent
hosts, a cell mediated T cell response is induced which leads to activation and
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recruitment of macrophages to the site of infection (102). Alveolar macrophages and
phagocytes such as dendritic cells (DCs) and neutrophils are the first cells to interact
with the bacilli (18). M. tb replicate in naïve macrophages and remain confined in the
intracellular compartment for extended periods (69). Bacilli can however be released at
any time following immune suppression (102). M. tb infected macrophages are
transported via the lymph and blood vessels to organs such as the spleen, liver and
lymph nodes (69) where T cells are primed and clonally expanded (23). Due to the
release of chemotactic factors, circulating monocytes will infiltrate the infection site and
differentiate into mature macrophages which are able to kill free bacteria (69).
Ultimately, progression from infection to disease, from latent TB infection (LTBI) to active
TB, is dependent on infection dose, immune status and other factors such as under
nutrition and toxins (alcohol, tobacco) (25).
1.3 Diagnosis of TB
In 100 - 200 AD the cause of TB was unknown and the disease was called
(amongst other names) phthisis, which means ‘wasting away’, and consumption.
Ulceration of the lung, chest or throat, together with coughs and fever were observed.
Since the discovery of X-Rays by Wilhelm Konrad von Roentgen in 1895, the
progression of disease and its severity could be well documented in TB patients (58). In
1891 a compound called tuberculin, prepared from liquid culture of tubercle bacilli, was
isolated by Robert Koch in order to use it as a therapeutic vaccine against TB. Although
tuberculin treatment failed, its use as diagnostic tool for M. tb infection was discovered.
Today Koch’s description of the preparation of tuberculin is used in the production of
purified protein derivative (PPD) of tuberculin which is used in the Mantoux test, known
as the tuberculin skin test (TST) (58). The TST is an in vivo test in which tuberculin is
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injected intradermally and, within 48-72 hours, a positive reaction, such as induration
and swelling, which is caused by delayed type hypersensitivity (DTH) reaction, is used
as measurement of infection. PPD consists of secreted and somatic proteins of M. tb
specific antigens, which is also found in M. africanum, environmental non tuberculosis
mycobacteria (NTM) and M. bovis Bacillus Calmette-Guérin (BCG) vaccine.
Consequently, the TST has a high sensitivity, but poor specificity for infection with M. tb
(96;105). Furthermore the TST cannot differentiate LTBI from active TB, which is a
problem particularly in high incidence areas (82). In developing countries the
identification of acid-fast bacilli (AFB) in sputum samples by smear microscopy, which is
based on the high lipid content of the cell wall of mycobacteria, is used as a standard
test to diagnose TB. This diagnostic method is however problematic in HIV positive TB
cases, as they produce smear negative results, and children who fail to produce enough
sputum (21).
While smear microscopy needs 10 thousand bacilli per mL of sputum, the
GeneXpert only requires 150 bacilli per mL of sputum (57). The GeneXpert is a
polymerase chain reaction (PCR) based assay which only detects Deoxyribonucleic acid
(DNA) of the M. tb complex (MTBC) and not NTMs. The GeneXpert can be used on
smear positive and negative samples. While the GeneXpert can only detect resistance
to Rifampicin (RMP), other polymerase chain reaction (PCR) tests such as the Line
Probe Assay can detect both RMP and isoniazid (INH) resistance. The disadvantage of
the Line Probe Assays is that it can only detect M.tb on smear and culture positive
samples, which makes it necessary to culture the samples first (57;114).
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Other assays rely on proliferation of lymphocytes after exposure to M. tb antigens.
Accurate detection of M. tb infection, without detection of NTMs or M. bovis BCG,
antigens specific for M. tb had to be used. The region of difference 1 (RD1) contains
antigenic proteins which are restricted to the M. tb complex; the 6-kDa early secreted
antigen target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) (60;105). These
antigens have been used in two commercial interferon gamma release assays (IGRAs),
the QuantiFERON-TB GOLD (together with TB7.7) and the T-SPOT.TB test. These tests
determine the amount of interferon gamma (IFN-γ) secreted by T cells stimulated with
TB specific antigens (74). Only T cells of sensitized individuals who have re-
encountered M. tb antigens will produce IFN-γ. The T-SPOT.TB test is an in vitro test in
which mononuclear cells are stimulated with ESAT-6 and CFP-10. Effector cells, T cells
which have recently been exposed to the TB antigens, will be able to produce IFN-γ
(54), while memory T cells are less likely to produce IFN-γ due to the short incubation
time (96).
The QuantiFERON-TB GOLD test is an Enzyme Linked Immunosorbent Assay
(ELISA) based test whereby IFN-γ in culture supernatant is measured by ELISA (96).
Even though both these tests show high sensitivity and specificity (105) neither
differentiates between active and latent TB and the performance remains poor in
children (17) and immunosuppressed individuals (60).
Discordance between TST and IGRA results has also been shown. While the IGRA
is a short time assay and only effector T cells are detected, the T cells in the TST test
have time to expand into memory T cells (17). Overall it is believed that the IGRA is
more specific than the TST (74). The TST leads to more indeterminate results in HIV
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positive individuals and in young children (105), which is a problem as those groups are
of much higher risk to progress to active disease from LTBI (1). It has been shown that a
decrease of CD4 T cells leads to more indeterminate results, which makes it less
sensitive in HIV positive individuals (1;78;103).
1.4 Treatment
In the 19th century very little information about TB and its appropriate treatment
was available. In 1854 Hermann Brehmer, who suffered from TB, travelled to the
Himalayas where he was exposed to the specific climate of the area and got cured. He
wrote his medical dissertation “Tuberculosis is a Curable Disease”, propagating good
nutrition, bed-rest and fresh air as a cure, and subsequently sanatoria were introduced
all over Europe (64). After 1919 more drastic methods were applied such as lung
volume reduction by artificial pneumothorax and surgery, but those methods became
dangerous and controversial. By 1943 the antibiotic streptomycin was found to be
effective against TB. Other drugs such as para-aminosalicylic acid (PAS) and INH also
have been shown to cure TB, but mycobacteria quickly developed resistance and only a
combination of the three drugs proved better than in a single dose (58). Today INH is
still employed as a first line drug together with RMP, Pyrazinamide (PZA) and
Ethambutol (EMB) in the 2-month intensive phase of treatment, followed by 4 months of
INH and RMP. TB drugs must be bactericidal, bacteriostatic, or have the ability to
prevent resistance. INH is bactericidal after 24 hours and kills over 90% of the rapid and
intermediate growing bacilli in the first 2 days. RMP and PZA are also bactericidal and
are used as sterilizing agents, whereas EMB is bacteriostatic and used to minimize the
emergence of drug resistance (72).
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1.5 Host immune response
The growth of M. tb can be controlled in healthy people by the innate and adaptive
immunity which results in the secretion of appropriate chemokines and cytokines (
Figure 1.3). Due to primary progression or reactivation some people will develop active
TB (37). T cells play a vital role in the immune response to M. tb as they lead to
activation or cytolytic activity of macrophages (46).
Figure 1.3: The innate and adaptive immune system. (Figure adapted from
http://www.rikenresearch.riken.jp)
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1.5.1 Innate Immunity
Innate phagocytes serve as antigen presenting cells (APCs) and contain several
receptors (pattern-recognition receptors; PRRs) able to recognize M. tb components.
Such receptors include Toll-like receptors (TLRs), C-type lectin receptors (CLRs) and
cytosolic pattern recognition receptors, and induce expression of pro-inflammatory
cytokines, chemokines and adhesion receptors after stimulation (27). In an attempt to
contain the infection, granulomas are formed which consist of different cell populations
such as alveolar macrophages, Langhans giant cells, T cells and DCs. In the
granuloma, macrophages and Langhans giant cells surround the intracellular
mycobacteria and present processed M. tb antigens to the T cells via major
histocompatibility complex (MHC) class II molecules. T cells are activated upon antigen
recognition and secrete cytokines and chemokines which recruit cells from circulating
blood, and activate macrophages and APCs to kill the bacteria. M. tb activated
macrophages release IL-12, leading to the development of T helper 1 (TH1) cells (77)
and their release of TH1 cytokines (14;23;30). The formation of the granuloma wall is
mediated by Tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta
(TGF-β) secretion by CD4 T cells and macrophages which prevents pathogen
dissemination (30;46;104). Together with IFN-γ, TNF-α induce antimycobacterial effects,
such as the production of nitric oxide and related reactive nitrogen intermediates (RNI)
by macrophages (27).
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1.5.2 Adaptive immunity
Innate immune responses to M. tb infection establish an environment that allows
development of adaptive immunity. The adaptive immune responses consist of cell
mediated and humoral immunity.
Cell mediated immunity
During M. tb infection, activated antigen-specific CD4 T cells (30) play an important
role in the protection against M. tb (38;46). Protective cell mediated immunity to M. tb is
associated with the development of TH1 responses and production of TH1 cytokines
such as IFN-γ, IL-2, TNF-α (3). On the other hand, the release of IL-4 leads to
development of TH2 responses, such as IL-4, IL-5, IL-13 and IL-10 and support of B cell
growth and differentiation (51). TH2 responses can induce suppression of TH1
immunity, thereby impairing control of M. tb infection (23). While TH2 cells drive the
humoral immunity through up-regulation of antibody production (particularly
immunoglobulin G1 and immunoglobulin E) to subsequently fight extracellular
organisms, the TH1 cells drive the cellular immunity to overcome viruses and
intracellular pathogens, to raise DTH and fight cancer (22;49;116). CD4 T cells can also
develop into TH17 cells due to the release of IL-23, IL-6, and IL-21, and produce IL-17
and IL-22, which stimulates defensin production and the recruitment of monocytes to the
inflammatory site. Chen et al. have shown that patients with tuberculosis show a
suppressed TH17 response, which is associated with the clinical outcome of M. tb
infection (13).
The role of CD8 T cells in TB less compelling, but increasing evidence suggests
they promote immunity against M. tb by contributing to long-term protection (54). Some
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CD8 T cells possess CD4 receptors, and are referred to as precursor T cells, mainly
observed in neonates. M. tb antigens are presented to CD8 T cells via MHC class I
molecules (14;54). Recognition of M. tb infected cells by CD8 T cells induce secretion of
IFN-γ and lysis of infected cells via exocytosis of granules containing perforin and
granzymes (46;98). Lysed cells release mycobacteria in the extracellular environment,
facilitating uptake by activated macrophages (14). Due to the high frequency of CD8 T
cells in peripheral blood their effector function is observed as early as 12 hours after
exposure to antigen, highlighting their effective role as killer cells during M. tb infection
(30;47).
Following proliferation and differentiation, a subset of effector T cells develop into
memory T cells which are able to respond faster after re-exposure to an antigen. The
expression of several surface markers distinguishes between naïve and memory T cells
(71). Memory T cells can be distinguished from naïve T cells (Tnaïve) via the memory
marker CD45RO. Through the expression of homing receptors such as CD62L or
CCR7, memory T cells can be further divided into central memory (TCM, CD62L+) and
effector memory T cells (TEM, CD62L-)(79;88). T cells expressing these homing
receptors are able to migrate to secondary lymphoid organs (88). TCM and TEM are also
distinguished by their expression of the IL-7 receptor alpha (CD127). CD127 is
expressed upon exposure of naïve T cells to an antigen, which gets cleared and leads to
a re-expression of CD127 on memory cells. After antigenic stimulation TCM, which
produce a large amount of IL-2, proliferate to TEM and are able to produce multiple
cytokines such as IFN-γ, IL-2, TNF-α, Granulocyte-macrophage colony-stimulating
factor (GM-CSF) or IL-4. TCM are mainly found as CD4 T cells, while TEM have also been
found as CD8 T cells. Due to the expression of CD45RA a fourth subpopulation,
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terminally differentiated effector memory T cells (TEMRA), are found in the in CD8 TEM
subset. These cells do not express CD62L and down regulate CD45RO (88). Regulatory
T cells (Treg) develop from CD4 T cells through the release of IL-2 and high
concentrations of TGF-β, which in return produce IL-10 and TGF-β (23). A dominating
phenotype is the expression of CD25 and CD25 high on CD4 T cells, which is increased
in active TB cases (81;99). The detrimental role of Tregs in TB was shown by various
studies such as Ribeiro et al. (81), reporting their suppression of IFN-γ production and
increase in IL-10 and TGF-β, leading to decreased T cell function.
T cells contain two types of T cell receptors (TCR), composed of α and β chains, or
γ and δ chains (42;89). While α and β chain containing CD4 and CD8 T cells make up
the majority of T cells in peripheral blood, γδ T cells represent only 1-5% percent of
peripheral blood lymphocytes. γδ T cells act as non-classical T cells that cross link
innate and adaptive immunity and are, along with natural killer (NK) cells, the first cells
to express IFN-γ, well before IL-12 secreting APCs initiate the expression of IFN-γ in
adaptive T cells (66). It is well established that patients with pulmonary TB express
increased frequencies of γδ T cells in peripheral blood (41). The presence of γδ T cells
in alveolar spaces of pulmonary TB patients, also suggests that alveolar macrophages
serve as APCs for γδ T cells (92).
Since the discovery of the characteristic TH1, TH2, TH17 and Treg polarized T cell
subsets (70), other subsets such as TH9 have been described. Initially, IL-9 was thought
to be expressed by TH2 cells, but Veldhoen et al. (108) showed that IL-9 producing T
cells were distinct from TH1, TH2, Treg and TH17 cells. They showed that TGF-β alters
TH2 cells, resulting in loss of IL-4 and, IL-5 and IL-13 production and initiation of IL-9
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production. It has been shown that peripheral blood mononuclear cells (PBMCs) from
TB patients express increased levels of IL-9 when stimulated with ESAT-6 and that the
expression of IFN-γ could be decreased by neutralization of IL-9. These findings support
the hypothesis that TH1 responses are induced by IL-9 production (115).
The interaction of CD40 and CD40L (CD154) plays a role in cellular and humoral
immunity. CD40 is a surface receptor first identified on B lymphocytes, while its ligand
CD40L, was recognized on activated CD4 T cells including TH0, TH1 and TH2 cells
(106). More recent evidence shows that CD40L is also expressed on cytotoxic T
lymphocytes (CTL) (90), memory T cells (86), NK cells (9), macrophages (5), basophils
(34), and eosinophils (33), and CD40 on activated T cells (86), macrophages (5) and
dendritic cells (76). The activation of naïve T cells requires antigen-specific signaling via
TCR as first signaling pathway, co-stimulatory molecules CD80/ CD86 on APCs and the
presence of cytokines. The co-stimulatory molecule interacts with CD28 on T cells and
forms the second signaling event (91). Only in the presence of a third signal which is
provided by essential cytokines such as IL-12, a full activation and differentiation can be
achieved (73). CD40L is subsequently expressed on memory cells, which produce TNF-
α, IL-2 or IFN-γ (10).
Humoral immunity
While CD4 T cells mainly target intracellular microbes, antibodies can recognise
extracellular microbes. Antibodies are important in neutralization and prevention of
invasive pathogens, especially at the mucosal surface (56). Since TB is primarily a
respiratory mucosal disease, there is renewed interest in the potential protective role of
M. tb-specific antibodies, against TB (80;110). Senol et al. showed that the humoral
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antibody response to mycobacterial antigens could be a significant diagnostic indicator
of active pulmonary TB. They showed that the serological response to combined 38-kDa
and 16-kDa M. tb antigens was higher in actively diseased TB patients compared to
those previously treated for TB with a negative a sputum smear and culture (95).
1.5.3 Immune regulation through Cytokines
All cytokine responses are interconnected and shape the outcome of host infection
as they regulate all cells of the immune system (30). Although much is known on the
role on each individual cytokine, insufficient information exists on the combined role of
the cytokine repertoire and their linked interactions. TNF-α is an proinflammatory
cytokine (44) activating chemokine production which attracts leukocytes to inflamed
tissues and normal secondary lymphoid organs (94). TNF-α is produced by
macrophages, DCs and T cells and its primary role is to limit replication of M. tb (111).
For this reason, TNF-α is particularly relevant during the early stages of infection to
control acute M. tb infection (31). As described earlier, TNF-α is also important in
granuloma formation (30) as it forms the granuloma wall together with TGF-β and is
responsible for caseous necrosis (31). Together with IFN-γ it plays an important role in
defense against intracellular pathogens such as M. tb (30). IFN-γ is an important
mediator of macrophage activation in M. tb (55), is secreted from activated T cells and
NK cells and is also responsible for the formation of granulomas and killing of cells (23).
IL-2 is a potent T cell growth factor and plays a critical role in clonal expansion of
memory T cells (43). A study by Lalezari et al. has shown that treating HIV infected
participants with low dose IL-2 leads to increase of CD4 count, and expansion of NK
cells and naïve T cells (53). GM-CSF stimulates growth of granulocytes, activates
macrophage functions (15) and inhibits bacterial growth (101). M. tb H37Rv infection
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models in mice have shown that treatment with IL-2 and GM-CSF decreases the
bacterial load in the lungs and spleen and those mice showed a higher survival rate
compared to untreated mice (117).
1.6 TB vaccination
BCG vaccine, an attenuated M. bovis strain developed by Albert Calmette and
Camille Guérin in 1921 (47;72), is widely used and routinely given to infants at birth in
countries with high burden of TB (112). BCG is ineffective in preventing TB in adulthood,
but has been shown to prevent TB meningitis and miliary TB in children (72). The
effectiveness of BCG depends on the age of the vaccine recipient, virulence of the
infecting M. tb strain, co-infection with other pathogens such as helminthes or HIV,
exposure to environmental mycobacteria and other factors that influence the immune
response such as malnutrition (23). The variability and poor efficacy of BCG steered
research into the development of improved vaccines against TB. However, opposing
views exist in the scientific community on the most suitable replacement or booster
vaccine for BCG. Some suggest development of a vaccine which neutralizes the
production of an M. tb protein essential for virulence (73). Others endorse development
of a vaccine containing the attenuated and avirulent strain of M. tb to induce an immune
response (16). The question remains: if BCG shares approximately 95% homology with
M. tb, why is it still not effective (30)?
Currently many TB vaccines, based on the various suggestions mentioned above,
are in the pipeline (Table 1.1). Most of these can be divided into subunit vaccines, which
can further be divided into adjuvant- or viral vector based and whole mycobacterial
based vaccines. Subunit vaccines present one or more immunogenic M. tb antigen(s).
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Examples of such vaccines are Aeras-402 (2) and MVA85A (65) consisting of a modified
vaccinia Ankara. Adjuvant based vaccines such as the GlaxoSmithKLine M72 and
Aeras-404 , rely on adjuvant fusion proteins (85). Modified strains of BCG are also used
in whole mycobacterial vaccines. These modified strains have been manipulated to
overexpress TB antigens, such as antigen 85B in rBCG30, altering the immune
response which leads to overexpression of listeriolysin in VPM1002, or Aeras-422 which
overexpresses listeriolysin, antigens 85A, 85B and 10.4 (11).
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Status Vaccine Vaccine description Type of vaccine Target population
Phase III Mw [M. indicuspranii (MIP)]
Whole cell saprophytic non‐TB
mycobacterium
Whole cell,
Inactivated or
Disrupted
Phase III
(completed)
M. vaccae Inactivated whole cell non‐TB
mycobacterium;
phase III in BCG‐primed HIV+
population completed; reformulation
pending
Whole cell,
Inactivated or
Disrupted
BCG‐vaccinated HIV+
adults
Phase IIb
MVA85A/Aeras‐485 Modified vaccinia Ankara vector
expressing Mtb antigen 85A
Viral Vectored BCG‐vaccinated infants
and adolescents; HIV
infected
adults
Aeras‐402/Crucell
Ad35
Replication‐deficient adenovirus 35
vector expressing Mtb antigens 85A,
85B, TB10.4
Viral
Vectored
BCG‐vaccinated infants,
children and adults
Phase II
M72 + AS01 Recombinant protein composed of a
fusion of Mtb antigens Rv1196 and
Rv0125 & adjuvant
AS01
Recombinant
Protein
Adolescents/adults,
infants
Hybrid‐I+IC31 Adjuvanted recombinant protein
composed of
Mtb antigens 85B and ESAT‐6 RecombinantProtein Adolescents; adults
VPM 1002 rBCG Prague strain expressing
listeriolysin and carries a urease
deletion mutation
Recombinant
Live
RUTI Fragmented Mtb cells Whole cell,
Inactivated or
Disrupted
HIV+ adults, LTBI
diagnosed
Phase I
AdAg85A Replication‐deficient adenovirus 5
vector expressing Mtb antigen 85A
Viral
Vectored
Infants; adolescents;
HIV+
Hybrid‐I+CAF01 Adjuvanted recombinant protein
composed of Mtb antigens 85B and
ESAT‐6 RecombinantProtein Adolescents, adults
Hybrid 56 + IC31 Adjuvanted recombinant protein
composed of Mtb antigens 85B,
ESAT‐6 and Rv2660 RecombinantProtein Adolescents, adults
HyVac 4/Aeras‐404,
+ IC31
Adjuvanted recombinant protein
composed of a fusion of Mtb antigens
85B and TB10.4
Recombinant
Protein
Infants
ID93/GLA‐SE Subunit fusion protein composed of 4
Mtb antigens
Recombinant
Protein
Adolescents, adults
Phase I
[completed]
Aeras‐422 Recombinant BCG expressing mutated
PfoA and overexpressing antigens
85A, 85B, and Rv3407
Recombinant
Live
Infants
rBCG30 rBCG Tice strain expressing 30 kDa
Mtb antigen 85B
Recombinant
Live
Newborns, adolescents,
and adults
M. smegmatis Whole cell extract Whole cell,
Inactivated or
Disrupted
Table 1.1: New Vaccines in pipeline. List of tuberculosis vaccine candidates which have been in clinical
trials in 2011. (http://www.stoptb.org/wg/new_vaccines/documents.asp)
The vaccines listed above are designed to induce a CD4 or CD8 T cell response
which can be assessed using different immunological assays. These assays can
measure cell mediated responses or the level of gene expression. The most common
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assay to measure immunogenicity in vaccine trials is the IFN-γ ELISpot. With the
growing and better understanding of flow cytometry, it has become a widely used assay.
Flow cytometry makes it possible to evaluate T cell responses in short term and long
term assays by re-stimulating cells with the antigen of interest. Flow cytometry has the
advantage over ELISPOT assays in that the researcher can identify the specific cell
populations producing the resultant cytokines (e.g. IFN-γ). Activation markers and innate
cell markers can be assessed by phenotyping, determining the proportion of T cells
expressing one, two , three or more cytokines/chemokines using a short term assay,
and the kinetics of immune responses can be assessed using proliferation assays,
mostly over 4-6 days (20). During vaccine trials, a blood for safety analysis has to be
drawn before blood for immunogenicity. Immunogenicity assays require a large amount
of blood, depending on the assays and which source of sample will be used (PBMCs or
whole blood) (28;39). Clinical phase I trials will be conducted in adults, where there is
enough blood available. Going further along the pipeline (phase II and III trials), the
blood volume becomes limited as those trials are done in infants (babies). These trials
follow specific guidelines on how much and how often blood can be drawn from infants,
which have to be strictly followed (39).
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1.7 Hypothesis
Taking all of the mentioned aspects into account I hypothesize that the
QuantiFERON in-tube assay system can be used to assess the immunogenicity of
vaccines using the one-tube for multiple immunogenicity assays with comparable results
to the established assays.
1.8 Aim of the study
The aim of the study is to develop a multi platform immune analysis assay using
the QuantiFERON in-tube assay system. Adaptations of the QFT assay to incorporate
antigen-specific cellular characterization (by flow cytometry) and soluble host marker
production (multiplex cytokine arrays) may have the advantage that multiple
complimentary immunological readouts can be obtained from a commercially available,
highly standardized M. tb antigen stimulated whole blood culture assay.
1.9 Objective of the study
To fulfill the aim of the study the following objectives have to be met:
i. IFN-γ ELISA must be performed to determine QFT status of community controls,
household contacts and TB cases.
ii. Luminex experiments to assess the expression of different cytokines in QFT
plasma from community controls, household contacts and TB cases.
iii. Phenotyping of QFT cells by flow cytometry.
iv. Polyfunctional T cells are assessed using QFT blood in short term whole blood
assay (QFT-WBA) and long term lymphocyte proliferation assay (QFT-LPA).
v. Ribonucleic acid (RNA) isolation of QFT cells.
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The most exciting phrase to hear in science,
The one that heralds new discoveries,
Is not 'Eureka!' but 'That's funny...'
Isaac Asimov
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2.1 Study Participants
2.1.1 Consent and Ethical Approval
Informed written consent was obtained from all participants. All participants were
volunteers and could terminate their participation in the study at any time without any
negative effect on their treatment.
Community Controls (CTRL), Household contacts (HHC) and TB index cases were
recruited at public health care clinics in urban areas in the Western Cape, specifically in
Ravensmead, Uitsig and Elsies River.
2.1.2 Inclusion Criteria
Study participants had to be willing to give written informed consent. They had to
be available for a TST reading after 48-72 hours after administration of the test and had
to be willing to undergo HIV testing. Participants had to be 15 years of age or older.
HHCs had to be in contact with a household member who had been diagnosed
with sputum smear positive TB in the past 4 months. The TB cases did not have to be
part of the study. A HHC had to have a positive TST.
A TB index case had to be newly diagnosed with active pulmonary TB (positive
sputum culture), or retreated for TB.
2.1.3 Exclusion Criteria
Participants who were on TB treatment for more than 7 days, were currently on
antiretroviral therapy (ART), participated currently or recently (past 3 months) in drug or
vaccine trials or were pregnant, were excluded from this study.
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2.1.4 Selection of Participant Cohort
The final participant cohort for the study consisted of three groups between 15 and
59 years of age. The first group included 16 household contacts, second group 19 TB
index cases and the third group 10 community controls. For all optimization steps six
laboratory controls (LC) were used with a mean age of 35.5 years. Two of the lab
controls have had previous TB, which also showed a positive QuantiFERON response.
2.2 Blood Collection and harvesting of samples
Items Company Catalog number
QuantiFERON®-TB Gold IT Blood
Collection tubes Cellestis T0590 0301
15mL tube LASEC PGRE188261
50mL tube LASEC PGRE227261
2mL Screw cap tubes LASEC PSOR12980
2mL Cryo vials LASEC PGRE126263
RNA later Ambion AM7021
Fetal Bovine Serum (FBS) Lonza DE14-80F1
10X Phosphate Buffered Saline
(PBS) Lonza BE17-517Q
Roswell Park Memorial Institute
(RPM 1640 Sigma R0883
L-Glutamin Sigma G7513
Dimethyl sulfoxide (DMSO) Sigma D8418
Brefeldin A Sigma B7651
Ionomycin Sigma I0634
Phorbol myristate acetate (PMA) Sigma P8139
FACS™ Lysing Solution BD 349202
BD Pharm Lyse™ lysing solution BD 555899
Table 2.1 Reagents and Consumables for Blood Collection and harvesting of samples
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2.2.1 Blood Collection
QuantiFERON® blood collection tubes are pre-coated with Sodium Heparin
(NaHep) and the antigens ESAT-6, CFP-10 and TB7.7 (p4) in the ‘Antigen’ tube. The
‘NIL’ tube serves as negative control to determine the background or nonspecific
binding. The ‘Mitogen’ tube is coated with Phytohaemagglutinin (PHA), and serves as
positive control as an indication for correct blood handling and incubation. About 1mL of
blood was drawn directly into each tube. To ensure proper mixing of blood with tube
contents, the tubes were shaken up and down 10 times. The QuantiFERON tubes were
transported to the laboratory at room temperature within 3 hours. To assure a constant
incubation time of 18h at 37°C the tubes were put in the incubator at 2pm and
processed at 8am the next morning.
2.2.2 Harvesting of samples
After 18h incubation of the QFT tubes, blood is mixed by inverting the tube.
Harvesting blood for RNA
At first 200μL of blood is removed and transferred into a 2mL tube containing
600μL RNAlater® Solution. Samples are then frozen at -80°C.
Harvesting blood for phenotyping
100μL of QuantiFERON blood were transferred into a 15mL tube containing 5mL of
1X BD FACS™ Lysing Solution, incubated for 10 minutes at room temperature and spun
down for 10 minutes at 400g. The supernatant was discarded and the pellet
resuspended in 0.5mL Roswell Park Memorial Institute (RPMI) media. 0.5mL of 20%
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DMSO in FBS was added drop wise to the tube and the content of the tube was
transferred into a 2mL cryo vial and frozen away in a Nalgene® Mr. Frosty container at -
80°C overnight, and thereafter transferred into liquid nitrogen.
Harvesting of plasma
After removing blood for RNA the tubes were centrifuged at 3000g for 10 minutes.
The gel plug in each tube separates the blood from the plasma and plasma can be
harvested. For each sample 3X 3 tubes were prepared (three for each stimulus). 80µL of
plasma was harvested into the first two tubes. The remaining plasma was harvested into
the last tube. All tubes were stored at -80°C until human IFN-γ ELISA and Luminex were
performed.
Harvesting of blood cells
In order to harvest the blood cells the QFT tubes were put upside down in a 50mL
centrifugation tube. The tubes were spun down for 1min at 400g. The whole blood is
now on top of the gel and can be removed carefully. The blood cells were harvested into
a 15mL centrifugation tube containing 5mL of 1X PBS. After removing the blood cells
the tubes were washed with the 1X PBS to harvest any remaining cells. After spinning
down the tubes for 10min at 400g the supernatant was removed carefully. About 500μL
of blood remained in the tubes and was split between the QFT-WBA and QFT-LPA.
For the QFT-WBA six 2mL tubes containing 10μg/mL Brefeldin A were prepared
and three of these tubes also contained PMA/ Ionomycin. 200μL of blood from each of
the NIL, Antigen and Mitogen tube were transferred into one of the tubes containing
Brefeldin A only and one of the tubes containing Brefeldin A, PMA and Ionomycin. The
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tubes were vortexed and incubated for another 4h at 37°C. After the incubation the
blood was transferred into 15mL tube containing 10mL of 1X BD FACS™ Lysing
Solution and incubated for 10min at room temperature in the dark following a
centrifugation step at 400g for 10min. Supernatant was discarded and cell pellet were
resuspended in 0.5mL RPMI. 0.5mL of 20% DMSO in FBS was added drop wise to the
tube and the content of the tube was transferred into a 2mL cryo vial and frozen away in
a Nalgene® Mr. Frosty container at -80°C overnight, and thereafter transferred into
liquid nitrogen.
For the QFT-LPA a 96 well plate was prepared. Six wells were allocated to each
patient sample. PMA and Ionomycin were added to half of the wells. Following the same
principle as in the WBA, 50μL blood of each of the NIL, Antigen and Mitogen tube was
transferred into a well with and without PMA/ Ionomycin. 150μL of RPMI containing 1%
L-Glutamine was added to each well. The plate was incubated for 6 days at 37°C. On
day 6 Brefeldin A was added into each well and PMA/ Ionomycin into stimulated wells,
followed by 4h incubation. After the incubation the blood was transferred into 15mL tube
containing 5mL of 1X BD FACS™ Lysing Solution and incubated for 10min at room
temperature in the dark following a centrifugation step at 400g for 7min. Supernatant
was discarded and cell pellet was resuspended in 1mL BD Pharm Lyse™ lysing
solution, filled up to 5mL with the same buffer, incubated for 10min at room temperature
and spun down at 400g for 7min. Supernatant was discarded and pellets resuspended
with 0.5mL RPMI. 0.5mL of 20% DMSO in FBS was drop wise added to the tube and
the content of the tube was transferred into a 2mL cryo vial and frozen away in a
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Nalgene® Mr. Frosty container at -80°C overnight, and thereafter transferred into liquid
nitrogen.
2.3 Cytokine expression in Supernatant
2.3.1 QuantiFERON®-TB Gold ELISA
The QuantiFERON®-TB GOLD ELISA test is a test for Cell Mediated Immune
(CMI) responses against mycobacterial proteins. It is used as an in vitro diagnostic test
of latent M. tb infection by measuring the amount of IFN-γ produced by stimulated cells
in whole blood.
Items Company Catalog number
QuantiFERON®-TB Gold IT kit Cellestis 0594-0201
Table 2.2 Reagents for QuantiFERON®-TB Gold ELISA
One hour before starting the ELISA, plasma was thawed and reagents from the
QuantiFERON®-TB GOLD ELISA kit, except 100X concentrate was brought to room
temperature. Assay strips were labeled to prevent switching of samples. In this study
‘NIL’, ‘TB Antigen’ and ‘Mitogen’ tubes were used. Therefore a Sample Layout (Figure
2.1) for 27 Samples and 1 internal lab control was used, including a four concentration
standard series in triplicate. Once the reagents have reached room temperature the
standard was made up by reconstitution with distilled water to give a concentration of 8
IU/mL. The vial was mixed gently to minimize frothing and the freeze-dried Kit Standard
was dissolved completely. Furthermore a 1:4 dilution series in Green Diluent was
produced. Standard 1 contains 4 IU/mL, Standard 2 contains 1 IU/mL, Standard 3
contains 0.25 IU/mL, and Standard 4 contains 0 IU/mL (Green Diluent alone). The
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standard dilution series was made up as follows (Figure 2.2): 4 tubes were prepared and
labeled with S1, S2, S3 and S4. Green Diluent was added into the tubes. S1 contains
150µL while S2-S4 contains 210µL. 150µL of the reconstituted Kit Standard was added
to tube S1 and mixed thoroughly. From S1 70µL were transferred to S2 and mixed
thoroughly. From S2 70µL were transferred into S3 and mixed thoroughly. S4 only
contains green Diluent and serves as zero standard.
Figure 2.1: Sample Layout for QuantiFERON ELISA using NIL, TB-Antigens and Mitogen. S1-S4
indicates the Standard Series; N indicates NIL control plasma; A indicates TB-Antigen plasma; M
indicates Mitogen control plasma, 1-27 indicated the different samples. An internal control was used for
Sample 28.
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Figure 2.2: Preparation of Standard dilutions (adapted from Cellestis QuantiFERON®-TB Gold
handbook)
The freeze-dried Conjugate 100X Concentrate was reconstituted with 0.3mL
distilled water and mixed well until dissolved completely. A working solution was
prepared by pipetting 60µL of reconstituted 100X Conjugate into 6.0mL of Green Diluent
in a 15mL tube.
50µL of working solution was added into each well using a multichannel pipette.
Plasma was mixed and 50µL added into the specific wells using a multichannel pipette.
The tips were discarded after each pipetting step. Finally 50µL of the standards 1 to 4
were added to each well S1 to S4. The plate was mixed carefully and incubated for 2
hours at room temperature in the dark.
While incubating a 1X washing buffer was made up using 100mL Wash Buffer 20X
Concentrate and 1900mL distilled water. The ELISA plate was washed 10 times per
hand with 1X wash buffer. For the performance it is really important that the wells get
filled with wash buffer. The plate was tapped upside down on an absorbent towel. At this
step it can happen that the strips fall of. Therefore it is important that they have been
Stellenbosch University http://scholar.sun.ac.za
CHAPTER TWO METHODS
30
labeled properly. 100µL of Enzyme Substrate Solution were added to each well and
mixed. The plate was incubated for 30min at room temperature while kept in the dark.
While incubating the micro plate the ELISA reader was started up. 50µL of Enzyme
Stopping Solution was added to each well and the Optical Density (OD) was measured
within 5min.
Raw data were analyzed and calculated using the QuantiFERON ®-TB GOLD IT
Analysis Software from Cellestis. As a quality control the software calculates and reports
the following parameters (from Cellestis hand book; Figure 2.3):
 The mean OD value for Standard 1 must be ≥ 0.600.
 The % coefficient of variation (CV) for Standard 1 and Standard 2 replicate OD
values must be ≤ 15%.
 Replicate OD values for Standard 3 and Standard 4 must not vary by more than
0.040 OD units from their mean.
 The correlation coefficient (r) calculated from the mean absorbance values of the
standards must be ≥ 0.98.
 The mean OD value for the Zero Standard should be ≤ 0.150.
If any of these criteria are not met the run is invalid and has to be repeated.
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Figure 2.3: Interpretation Flow Diagram (adapted from Cellestis QuantiFERON®-TB IT Gold
handbook); when the result is positive M. tb infection is likely, when the result is negative M. tb infection is
NOT likely, when the results indeterminate it is indeterminate for TB-Antigen responsiveness.
2.3.2 Bio-Plex Pro Assay (Luminex)
Bio-Plex Pro Assay is an assay to quantify multiple protein biomarkers, which are
secreted by many cell types, in a single well with as little as 12-25µL supernatant or
plasma. In the present study a 27-Plex assay was used containing the following marker:
IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17,
Basic fibroblast growth factor (FGF), Eotaxin, Granulocyte colony-stimulating factor (G-
CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, IP-10,
Monocyte chemotactic protein (MCP)-1, Macrophage inflammatory protein (MIP)-1α,
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MIP-1β, Platelet-derived growth factor (PDGF)-BB, Regulated and normal T cell
expressed and secreted (RANTES), TNF-α and Vascular endothelial growth factor
(VEGF).
Items Company Catalog number
Bio-Plex Pro Human Cytokine 27-
Plex Assay Bio-Rad M10-0KCAF0Y
Table 2.3: Reagents for Bio-Plex Pro Assay (Luminex)
Preparation of standard and reagents
Before starting the assay the samples and standards were brought to room
temperature.
For the reconstitution of the standard it was ensured that the pellet was at the
bottom of the vial by tapping the vial gently on the lab bench. 500µL of standard diluents
was added to the vial, vortexed for 1-3 sec and incubated for 30min on ice. While the
standard was incubating, the samples were prepared. For the preparation of the dilution
series, nine 1.5mL tubes were labeled S1 to S8 and Blank. 150µL of standard diluents
were added to tubes S2 to S8 and Blank, while S1 only got 72µL. The reconstituted
standard was vortexed gently for 1-3 sec and 128µL were transferred into tube S1,
containing 72µL of standard diluents. After each dilution the tube was vortexed for 1-3
sec and a new pipette tip was used to transfer 50µL from S1 to S2, S2 to S3 up to S8.
The diluted standard was used immediately.
For this assay QuantiFERON plasma was used, which was diluted 1:4 by adding
20µL sample to 60µL Bio-Plex sample diluent. The samples were kept on ice until
usage.
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For the preparation of the beads, 5,175µL of assay buffer was added to a 15mL
tube. The beads were vortexed for 30 sec at medium speed. The cap was opened
carefully and remaining liquid in the cap was pipette back into the tube. 575µL of 10X
beads were transferred into tube containing the assay buffer. The beads had to be
protected from light at all time and adjusted to room temperature before use.
Figure 2.4: Plate layout for Bio-Plex Pro Assay. Standards (S1-S8) and blank (Bl) were added in
duplicates while control (C1/C2) and samples (1-38, NIL (N) and Antigen (A)) were added as single wells.
Assay Procedure
The diluted beads were vortexed for 30 sec at medium speed, poured into a
reagent reservoir and 50µL were added into each well using a multichannel pipette. The
wells were washed twice using the Bio-Plex Pro™ Wash Station. The standard dilutions,
samples and controls were vortexed gently for 1-3 sec and 50µL were added to the
appropriate wells (Figure 2.4). The plate was sealed with a cover and incubated on a
shaker at room temperature for 30min. During the last 10min of the incubation time 1X
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detection antibody was prepared by adding 300µL of 10X detection antibody (vortexed
for 15-20 sec at medium speed) to 2,700µL of detection antibody diluent in a 15mL tube.
Once the sample incubation was over, the sealing tape was removed and the plate was
washed three times. The diluted detection antibody was vortexed for 1-3 sec, poured
into a reagent reservoir and 25µL were added into each well using a multichannel
pipette. The plate was covered with a new sealing tape and incubated on a shaker for
30min at room temperature. During the last 10min of the incubation 1X Streptavidin-
Phycoerythrin (PE) was prepared by adding 60µL 100X Streptavidin-PE (vortexed for 15-
20 sec at medium speed) to 5,940µL assay buffer in a 15mL tube. After incubation of the
detection antibody, the sealing tape was removed and the plate washed three times.
The diluted Streptavidin-PE was vortexed for 3-5 sec, poured into a reagent reservoir
and 50µL were added into each well using a multichannel pipette. The plate was
covered with a new sealing tape and incubated on a shaker for 10min at room
temperature. Once the incubation time was over, the sealing tape was removed, plate
washed three times and 125µL of assay buffer was added to each well. The plate was
covered with a new sealing tape, incubated on shaker at room temperature at 1,100rpm
for 30 sec. The plate cover was removed and the plate read using Bio-Plex High-
Throughput Fluidics (HTF) System.
2.4 Flow Cytometry
Flow Cytometry is a method to characterize single cells using different parameters
such as granularity, size, surface and intracellular structure as well as functional
characteristics like intracellular staining (ICS) and proliferation.
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Items Company Catalog number
FBS Lonza DE14-80F1
10X PBS Lonza BE17-517Q
IC Fixation Buffer eBioscience 00-8222-49
10X Permeabilization buffer eBioscience 00-8222-56
BD™ CompBeads Set Anti-Mouse
Ig, κ BD 552843
BD™ CompBeads Set Anti-
Rat/Hamster Ig, κ BD 552845
BD Cytometer Setup and Tracking
Beads BD 641319
Table 2.4: Reagents and Consumables for Flow Cytometry.
For all flow cytometry analysis a 96-well plate was used. 15mL tubes containing
2% FBS in PBS were prepared. The cryo tubes were taken out from liquid Nitrogen and
placed in a 37°C water bath to thaw. The thawing process was observed and as soon
only a small bit of ice was left, the tubes were taken out. 1mL of 2% FBS/ PBS was
taken out of 15mL tube and slowly added to the cryo tube. The content of the cryo tube
was transferred into a 15mL tube and spun down for 10min at 400g. The supernatant
was discarded, the remaining sample transferred into a well of a 96-well plate and used
for phenotyping or ICS, depending on sample.
2.4.1 Phenotyping
The plate containing the samples was spun down for 5min at 400g. The
supernatant was discarded and the remaining cells stained with 20µL of the antibody
mix (Table 2.5) and incubated for 20min at 4°C. Cells were washed twice with 200µL of
2% FBS/ FCS, resuspended in 200µL and run on a BD FACSCanto II.
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Antibody Fluorochrom Volume per sample [µL]
CD3 Pacific Blue 0.75
CD4 Horizon V500 1.00
CD8 Phycoerythrin-cyanine (PE-Cy)7 0.25
CD14 PE 0.25
CD19 Allophycocyanin (APC) 0.25
TCR γδ Fluorescein isothiocyanate (FITC) 0.75
2% FBS/ PBS 16.75
Table 2.5: Antibody master mix for phenotypic analysis. Antibody mix was prepared during the last
washing step and 20µL were added into each well using a multi channel pipette.
2.4.2 Intracellular Cytokine Staining
The plate containing the samples was spun down for 5min at 400g. The
supernatant was discarded; the remaining cells resuspended in 100µL IC Fixation buffer
and incubated for 20min at room temperature. The plate was spun down for 5min at
400g and washed twice with 1X Permeabilization buffer. The supernatant was
discarded; the remaining cells were stained with 20µL of the antibody mix (Table 2.6)
and incubated for 20min at room temperature in the dark. Cells were washed twice with
1X Permeabilization buffer, resuspended in 200µL and run on a BD FACSCanto II.
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WBA LPA
Antibody Fluorochrome Volume persample [µL]
Volume per
sample [µL]
CD3 Pacific Blue 0.75 0.75
CD4 Horizon V500 1.00 -
CD8 PE-Cy7 0.25 0.25
CCR7 APC - 0.50
CD45RA Horizon V500 - 0.75
Ki-67 FITC - 2.00
CD40L FITC 0.50 -
TNF-α PerCP-Cy5.5 1.00 1.00
IFN-γ APC-Cy7 0.50 0.50
IL-2 PE 0.75 0.75
IL-9 Alexa Fluor 647 0.75 -
1X Permeabilization buffer 14.50 13.50
Table 2.6: Antibody master mix for WBA and LPA. Antibody mix was prepared during the last washing
step and 20µL were added into each well using a multi channel pipette
2.5 Statistics
In all studies data were analyzed using GraphPad Prism 5. Multiple comparison
analysis using the Kruskal-Wallis test was done to determine differences between study
groups. Datasets which are not independent were analyzed using Wilcoxon matched
pairs test, such as data used for optimization, where same lab controls were used for
different experiments. Statistical significant differences were recorded as follow:
p > 0.05 not significant (ns)
p ≤ 0.05 *
p ≤ 0.01 **
p ≤ 0.001 ***
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Science is wonderfully equipped to answer the question "How?"
But it gets terribly confused when you ask the question "Why?"
Erwin Chargaff
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3.1 Introduction
This chapter describes the development of additional applications of the QFT
assay to incorporate antigen-specific cellular characterization (by flow cytometry) and
soluble host marker production (multiplex cytokine arrays). The advantage of this
approach would be that multiple complimentary immunological readouts can be obtained
from a commercially available, highly standardized M. tb antigen stimulated whole blood
culture assay.
3.2 Optimization of QFT assay for use in Flow Cytometry
With one third of the population infected with M. tb (114), TB remains a global
health problem. Diagnosis of TB is often a problem especially due to the lack of
sensitivity of the most widely used test, sputum smear microscopy, or high costs of more
sensitive diagnostic tools, like X-rays or GeneXpert, or due to difficulty in obtaining
adequate sputum sample especially in children. More cost efficient diagnostic tools are
necessary. In 2007, QFT-G was approved by Food and Drug Administration (FDA),
which measures IFN-γ responses to M. tb specific antigens (ESAT-6 and CFP-10) and is
used to detect asymptomatic or LTBI but cannot discriminate between LTBI and active
TB. By assessing QFT supernatants by Luminex, Chegou et al. (12) have shown that 3-
marker combination can differentiate between LTBI and active TB. It has also been
shown that cellular immunity plays a role in the control of M. tb infection and the analysis
of polyfunctional T cells by flow cytometry can help to understand the mechanism
(8;30;45). The hypothesis of the present work was that the QFT tubes would be useful to
evaluate a range of complementary antigen-specific immunological readouts, including
soluble marker expression, whole blood cell characterization by flow cytometry and gene
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expression analysis. The advantage of such an approach would be that a highly
standardized assay system would be used that requires only 3mL of blood, a major
benefit in pediatric participants of clinical trials, where blood volumes that are safely
obtainable are very limited.
The optimization for the usage of flow cytometry on cells from QFT tubes will be
discussed by comparing whole blood cells obtained from the QFT-WBA directly to cells
from a standard whole blood assay, whereby the optimal stimulation times and re-
stimulation methods will be addressed.
For all optimizations, whole blood from laboratory controls (LC) was used. In order
to compare the different assays, the same participant was used for WBA and QFT-WBA.
3.2.1 Removal of 300μL of whole blood from the QFT tubes does not affect IFN-γ
ELISA results
When using QFT for RNA isolation and phenotyping, blood was taken off before
harvesting the supernatant. It had to be assessed whether the removal of blood would
affect the QFT ELISA result.
1mL of blood from six lab controls was drawn into two sets of QFT tubes, each set
containing NIL, TB Antigen and Mitogen tubes. The tubes were incubated for exactly
18h at 37⁰C. After incubation the two QFT tube sets were split and one set was labeled
‘normal’ and the other ‘modified’. The normal QFT tubes were processed as per
manufactures guidelines, whereas 300μL were taken off from the modified QFT tubes
before processing. The supernatant was harvested into three tubes each, and frozen at -
80⁰C. For the QFT ELISA one NIL, TB Antigen and Mitogen tube from each set was
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processed as per manufactures guidelines. The results (Table 3.1) were obtained using
the QuantiFERON-TB Gold analysis software. To compare the results directly the values
for the normal and modified QFT were analyzed using GraphPad Prism 5 (Figure 3.1).
Lab
Control
Number
QFT NIL[IU/mL]
TB Antigen
[IU/mL]
TB Ag – NIL
[IU/mL] Result
LC 004 NORMAL 0.18 0.26 0.08 NEGATIVEMODIFIED 0.23 0.35 0.12
LC 005 NORMAL 0.13 0.49 0.36 POSITIVEMODIFIED 0.16 0.68 0.52
LC 006 NORMAL 0.05 8.62 8.57 POSITIVEMODIFIED 0.04 9.22 9.18
LC 007 NORMAL 0.04 0.04 0.00 NEGATIVEMODIFIED 0.03 0.03 0.00
LC008 NORMAL 0.04 0.04 0.00 NEGATIVEMODIFIED 0.05 0.04 -0.01
LC 009 NORMAL 0.11 0.07 -0.04 NEGATIVEMODIFIED 0.04 0.04 0.00
Table 3.1: QuantiFERON results of lab controls. The QuantiFERON-TB Gold analysis software
calculates the expression of IFN-γ in plasma by obtaining a standard curve. All the criteria described in the
method chapter were met and the test was declared as valid. The concentration of NIL, TB Antigen and
TB Antigen minus NIL are shown. Two out of six LCs were tested positive. There is no significant
difference between the normal and modified QFT.
NIL
QFT
normal
QFT
modified
IFN
-γ
[IU
/ m
L]
Antigen
IFN
-γ
[IU
/ m
L]
Mitogen
IFN
-γ
[IU
/ m
L]
QFT
normal
QFT
modified
QFT
normal
QFT
modified
Figure 3.1: Comparison of QuantiFERON results between normal QFT and modified QFT. 2 sets of
QFT tubes were filled with 1mL of blood from lab controls. Plasma was harvested as per manufactures
guideline (QFT normal) from one half while 300µL of blood were taking off from the other half (QFT
modified) before processing. ELISA was performed as per manufactures guideline.
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The comparison was done on six LCs. Two of the LCs had positive QFT tests with
both approaches. The concentration of IFN-γ for each stimulus between the normal and
modified assays was compared using the Wilcoxon matched pairs test. P values of 0.92
in NIL, 0.31 in Antigen and 0.50 in Mitogen tubes showed no significant differences and
the slight differences found probably reflect assay variability or pipetting errors.
The use of plasma and blood cells from the QFT can therefore be performed
without altering the QFT test result.
3.2.2 Comparison of WBA vs. QFT-WBA in flow cytometry
When following the manufactures guideline the blood has to pass through a gel
layer. The constituents of the gel layer are not shared by the manufacturer and it is
unknown whether this layer damages the white blood cells. To assess white cell viability
the QFT-WBA had to be compared directly to a WBA. Blood from LCs were drawn into
QFT tubes directly and 3mL was drawn into a NaHep tube. The whole blood from the
NaHep tube was transferred into a 24- well plate, each well containing 1mL of blood.
The blood was treated the same way as the QFTs, by adding 1 drop of ESAT-6 and
CFP-10 into the TB Antigen well, and 1 drop of Mitogen into the Mitogen well. The
Antigens and Mitogen were obtained from reagents of the QuantiFERON®-TB Gold
assay which has been discontinued and replaced by QuantiFERON®-TB Gold IT. The
blood was incubated for 18h at 37⁰C followed by harvesting of supernatant. The blood
cells from the QFT tubes were obtained by centrifuging the tubes upside down. The
blood cells were transferred into 2mL tubes, 200μL each, and incubated together with
10μg/mL Brefeldin A for another 4h. After the incubation period the red blood cells were
lysed, white blood cells were fixed and permeabilized, followed by staining with
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antibodies against human CD3, CD4, CD8 and IFN-γ. The cells were acquired on a
FACSCanto II instrument and analyzed with the FlowJo 7.6.5 and the percentage of
IFN-γ producing CD4 and CD8 T cells was determined using the gating strategy in
Figure 3.2. At first single cells were identified by gating on forward scatter-height (FSC-
H) versus forward scatter-area (FSC-A). The lymphocyte population was selected and
defined as CD3 T cells, which then was divided into CD4 and CD8 T cells. Further, the
expression of IFN-γ was determined by gating on those subpopulations. The data
obtained from FlowJo 7.6.5 were analyzed by Excel and GraphPad Prism 5 using the
Wilcoxon matched pairs test.
CD4
CD
8
FSC
SSC
FSC-A
FSC
-H
CD3
SSC
IFN-γ
SSC
IFN-γ
SSC
Figure 3.2: Gating Strategy used for all optimization steps. Flow cytometric analysis of IFN-γ
expression of T cells in stimulated whole blood cells. Firstly, cell doublets were excluded using forward
scatter-height (FSC-H) versus forward scatter-area (FSC-A). Using forward scatter (FSC) versus side
scatter (SSC) the lymphocyte population could be determined followed by identification of CD3 T cells,
which is further subdivided into CD4 and CD8 T cells. Cell specific expression of IFN-γ was subsequently
analyzed.
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Figure 3.3: Comparison of IFN-γ expressing CD4 and CD8 T cells in WBA and QFT-WBA. 1mL of
whole blood from LCs was stimulated with the same culture conditions as used for the QuantiFERON
assay. One set of QFT tubes were incubated for 22h. For the last 4h, Brefeldin A [10µg/mL] was added to
NIL control (A, D), Ag tubes containing ESAT-6/ CFP-10 (B, E) and MIT tubes containing PHA (C, F).
Intracellular staining was performed using antibodies against human CD3, CD4, CD8 and IFN-γ.
Concentration of IFN-γ expression in CD4 T cells (A, B, C) and CD8 T cells (D, E, F) was determined by
flow cytometry.
In the NIL control two of the six LCs show differences in IFN-γ expression, with one
sample showing an increase in the QFT-WBA while the other one shows a decrease
(Figure 3.3). The differences in the NIL tube are not significant, showing a p value of
1.00/ 0.56 (CD4/ CD8). In the Ag and Mitogen tube the QFT-WBA shows a higher
expression of IFN-γ compared the WBA. Significant differences were observed in the
IFN-γ expression of antigen stimulated CD4 T cells (p=0.03) and Mitogen stimulated
CD8 T cells (p=0.3). The higher expression of IFN-γ in QFT could be due to the
presence of TB7.7 as additional peptide, which may be responsible for the stronger
immune response in QFT. Overall the QFT-WBA shows good correlation with the WBA
method and can be used for flow cytometry.
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3.2.3 Comparison of 4h vs. 6h re-stimulation of QFT-WBA
The QuantiFERON tubes were incubating for 18h before harvesting the plasma. To
determine ICS, the transport of proteins to the cell surface has to be blocked by using
Brefeldin A. Brefeldin A leads to accumulation of cytokines at the Golgi complex which
then can be measured via ICS. To determine the optimal re-stimulation time, the blood
was incubated for another 4h and 6h in the presence of Brefeldin A. After the standard
18h incubation for the QFT test following the method described in the methods chapter,
the blood was harvested and divided into two tubes. One tube was incubated for 4h in
the presence of Brefeldin A; the second tube was incubated for 6h, whereby Brefeldin A
was added for the last 4h. After the incubation the red blood cells were lysed and ICS
was performed using antibodies against human CD3, CD4, CD8 and IFN-γ. The
percentage of IFN-γ expressing CD4 and CD8 T cells was determined and analyzed in
GraphPad Prism 5 using the Wilcoxon matched pairs test.
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Figure 3.4: Comparison of IFN-γ expressing CD4 and CD8 T cells in QFT cells stimulated for 4h
and 6h. After the initial 18h incubation, the QFT tubes were incubated for another 4h or 6h, whereby for
the last 4h Brefeldin A [10µg/mL] was added to NIL control (A, D), Ag tube containing ESAT-6/ CFP-10 (B,
E) and MIT tube containing PHA (C, F). Intracellular staining was performed using antibodies against
human CD3, CD4, CD8 and IFN-γ. Concentration of IFN-γ expression in CD4 T cells (A, B, C) and CD8 T
cells (D, E, F) was determined by flow cytometry.
The NIL tube showed an increase in most of the LCs in the 6h re-stimulation (Figure 3.4
Figure 3.4), while a few LCs showed a decrease in the Ag and MIT tube. Statistical
analysis does not show significant differences between the 4h and 6h assay with P
values of 0.25/ 0.38 (CD4/ CD8) in NIL, 0.69/ 0.44 (CD4/ CD8) in Ag and 0.15/ 0.20
(CD4/ CD8) in MIT. It was thus decided to use the 4h re-stimulation assay for all further
assays.
3.2.4 Different concentration of PMA/ Ionomycin used for QFT-WBA
Following an 18h incubation significant IFN-γ production and secretion into the
supernatant would have taken place. To ensure that meaningful additional production of
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this and other cytokines takes place after the addition of Brefeldin A, restimulation had to
be considered. One possible re-stimulation method would be through PMA and
Ionomycin, which stimulates the production of cytokines. To determine the optimal
concentration, whole blood was incubated with 2ng to 20ng of PMA and 200ng to 2µg of
Ionomycin, by maintaining a PMA/ Ionomycin ratio of 1/100, for a further 4h in the
presence of Brefeldin A. The optimization was done for an unrelated vaccine study,
performed by myself, where BCG and PHA were used as primary stimulus.
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Figure 3.5: Different concentrations of Ionomycin in stimulated whole blood. Whole blood from LCs
was stimulated with BCG (B, E) and PHA (C, F) and incubated for a total of 22h, whereby different
concentrations of PMA/ Ionomycin and Brefeldin A [10µg/mL] were added for the last 4h. Blood was lysed
and intracellular staining was performed using antibodies against human CD3, CD4, CD8 and IFN-γ.
Concentration of IFN-γ expression in CD4 T cells (A, B, C) and CD8 T cells (D, E, F) was determined by
flow cytometry.
The graph shows that in all samples the expression of IFN-γ increases with
increasing PMA/ Ionomycin concentration (Figure 3.5). Because the PMA/ Ionomycin
should only serve as a boost the high re-stimulation concentrations may also
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overshadow antigen-specific cytokine production, the lowest concentration, 2ng/mL
PMA and 200ng/mL Ionomycin, was used for further assays.
3.2.5 Different re-stimulation methods of QFT-WBA
To improve the cytokine expression after 18h culture in QFT tubes different re-
stimulation methods using anti CD28/ 49d, PMA/ Ionomycin and Ag or MIT from the
QuantiFERON®-TB Gold assay were investigated. Therefore QFT bloods from LCs
were incubated for 18h following a 4h re-stimulation in the presence of Brefeldin A plus
the different restimulation agents. One sample of each QFT tube was left without
restimulation to serve as control. The red blood cells were lysed and ICS was performed
using antibodies against human CD3, CD4, CD8 and IFN-γ. The percentage of IFN-γ
expressing CD4 and CD8 T cells was determined and analyzed in GraphPad Prism 5.
Differences between the restimulated sample and their unstimulated control were
calculated using the Mann-Whitney test.
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Figure 3.6: Different re-stimulation methods of QFT-WBA after harvesting of plasma. QFT from LCs
were incubated for 18h. After harvesting of plasma, blood cells were obtained and stimulated for another
4h with CD28/ CD49d, PMA/ Ionomycin and Antigen or Mitogen (depending on stimulus) in the presence
of Brefeldin A. Blood was lysed and intracellular staining was performed using antibodies against human
CD3, CD4, CD8 and IFN-γ. Concentration of IFN-γ expression in CD4 T cells (A, B, C) and CD8 T cells
(D, E, F) was determined by flow cytometry.
While the CD28/49d re-stimulation does not show differences for samples without
restimulation, a statistically not significant increase can be seen after Ag or MIT and
PMA/ Ionomycin addition (Figure 3.6). Because the Ag and MIT are not available
anymore (QFT Gold test was replaced by the QuantiFERON®-TB Gold IT test), all
further assays were done using PMA/ Ionomycin as re-stimulation.
3.2.6 Lymphocyte Proliferation Assay
Proliferation in T cells can be assessed using 3H-thymidine (a radioactive
substance) (12;75), and fluorescent dyes like Carboxyfluorescein succinimidyl ester
(CFSE) or Oregon Green (OG). OG is a visible light–excitable intracellular calcium
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indicator that is cell-permeate and loads into living cells. With each cell division the
relative fluorescent intensity of OG decreases by half. Oregon Green is excited at
488nm and emits light at 518nm, and shares the emission wavelength with FITC.
Therefore using flow cytometric analysis the different cell cycles can be assessed. In
order to use CFSE or OG, PBMC’s have to be isolated, whereas Ki-67 allows the use of
WB cells and is not limited to the FITC channel. Ki-67 is a protein which is expressed
during cell division and can be measured after stimulation combined with other markers
for phenotyping or ICS. Soares et al. (97) compared proliferation assays using OG in
PBMCs and Ki-67 in WB cells. They showed similar frequencies of proliferating T cells
and high reproducibility between the assays. They proposed Ki-67 as marker for
antigen-specific T cells proliferation. The advantage of using Ki-67 is the limited blood
volume required and that it requires no incubation or washing steps prior to incubation.
Using the above assay whole blood cells obtained from QFT tubes were stimulated for 6
days with PMA/ Ionomycin followed by re-stimulation with PMA/ Ionomycin for 4h after
addition of Brefeldin A.
3.2.7 Setting up FACSCanto II for Flow Cytometry
Many different reagents and fluorescent antibodies are available which react
differently under different conditions and therefore have to be optimized. The optimal
usages of marker have to be investigated in order to get the best results. Protocols have
to be adapted as the conditions in each laboratory are not the same and temperature
and humidity may influence the results. The Fluorescence Activated Cell Sorting (FACS)
Canto II is a sensitive machine. Equipped with three lasers it needs special attention as
the laser power varies from machine to machine and optimization has to be done
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specifically for the use of the machine otherwise it could result in false analysis of the
samples.
3.2.7.1 Antibody titration
For each experiment the antibodies had to be titrated to ensure optimal signal
compared to background noise. Too high concentration may result in non specific
binding. Whole blood cells from LCs were stained with different concentrations of
surface markers (Table 3.2). To assess the concentrations for ICS whole blood cells
were stimulated with PHA for 12h, followed by fixation and permeabilization. The data
were analyzed by determining the mean of the positive (signal) and negative population
(noise) for each antibody, and by calculating the signal/noise ratio.
After calculating the signal/noise ratio, antibody titration curves were plotted to
determine the saturating concentration (Figure 3.7). Most of the antibodies (human CD3,
CD4, CD8, CD40L, CD19, TCRγδ, Ki-67, IL-2 and IFN-γ) show a saturation point. At this
point the antibody shows the optimal separation between negative and positive
population. Antibodies like human CD45RA, Chemokine receptor 7 (CCR7), CD14 and
IL-9 show first a decrease in signal/noise ratio, followed by an increase until it reaches
saturation and decreases again. The decrease in those antibodies is only visible in
volumes lower than 0.5µL. Too few cells binding the antibody at the lower limit of
detection could affect the signal/noise ratio. Good separation was achieved when
reaching saturation. The only antibody which did not show a good signal/noise titration
curve was anti human TNF-α. The titration curve showed a continuous increase and did
not reach saturation even though the dot plot showed distinctive negative and positive
population.
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Antibody Fluorochrom I II III IV V
Su
rfa
ce
 st
ain
ing
CD3 Pacific Blue 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
CD4 V500 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
CD8 PE-Cy7 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
CD40L FITC 0.25 μL 0.50 μL 1.00 μL 2.00 μL 5.00 μL
CCR7 APC 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
CD45RA V500 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
Ki-67 FITC 0.25 μL 0.50 μL 1.00 μL 2.00 μL 5.00 μL
CD14 PE 0.125 μL 0.25 μL 0.50 μL 1.00 μL 2.00 μL
CD19 APC 0.125 μL 0.25 μL 0.50 μL 1.00 μL 2.00 μL
TCR γδ FITC 0.25 μL 0.50 μL 0.75 μL 1.00 μL
ICS
IFN-γ PE-Cy7 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
IL-2 PE 0.25 μL 0.50 μL 0.75 μL 1.00 μL 1.25 μL
IL-9 Alexa Fluor 647 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
TNF-α PerCP Cy5.5 0.25 μL 0.50 μL 0.75 μL 1.00 μL 2.00 μL
Table 3.2: Titration of surface antibodies and antibodies against intracellular cytokines.
Unstimulated whole blood was stained with different Titer of surface makers while PHA stimulated whole
blood was used for ICS. Bold values indicate optimal performance of the assay.
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Figure 3.7: Antibody titration plots. Evaluation of different antibody volumes by staining whole blood
from LCs with each antibody. The frequencies of positive populations (signal) and negative populations
(noise) was assessed by plotting the signal to noise ration into antibody titration curves. The circled point
in each graph shows the optimal titer, which was chosen for further flow cytometry assays.
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3.2.7.2 Compensation
Using 8-color flow cytometry requires good compensation as there is spill over
between emission spectra of different fluorochromes. To correct for the spillover
compensation had to be done, which allowed quantifying each single dye by subtracting
the portion of the spillover from one particular parameter into the other. For this study
compensation beads were used due to the many advantages; no cells are needed which
in some cases might be limited, dimly expressed antigens can still be compensated for,
guarantied negative and positive population.
Compensation was done for all three assays (phenotyping, WBA and LPA). The
compensation beads kit contained negative and positive beads. The negative beads
were uncoated and had no binding capacity whereas the positive beads were coated
with IgG kappa and bind to the immunoglobulin. For an 8-color experiment nine tubes
were prepared. One tube served as negative control and contained only negative and
positive bead, whereas the specific antibody was added to the other tubes containing
the negative and positive beads. The tubes were incubated for 15min, followed by a
washing step and compensation was run on FACSCanto II using FACS Diva software.
After defining the negative and positive population for each antibody the spectral overlap
was calculated. The compensations were used for all further assays.
3.3 Study population
The study groups used for the QFT assay consist of Community Controls (CTRLs),
Household Contacts (HHCs) and TB cases (TB) that were recruited from Ravensmead
and Uitsig. QFT from 10 CTRLs, 16 HHCs and 19 TBs were used for QFT IFN-γ ELISA,
Luminex and flow cytometry for immune cell phenotyping and ICS and QFT from 6
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CTRLs, 9 HHC and 11 TBs were used for LPA and RNA analysis. The demographic
characterization is shown in Table 3.3.
Community
Controls
Household
Contacts TB cases
Number of participants
For Luminex, WBA, Phenotyping
For LPA and RNA
10
6
16
9
19
11
Gender
Female
Male
4
6
11
5
5
14
Age in years
Mean
Age range
31.7
22-49
34.4
18-58
34.5
16-59
QFT results
Positive
Negative
not done
5
5
13
3
16
1
2
Table 3.3: Study population. Demographic characterization of study groups used for QFT assay.
3.4 Assessing the IFN-γ secretion in QFT supernatant.
The IFN-γ secretion in QFT supernatants was assessed using the
QuantiFERON®-TB GOLD ELISA assay as per manufacturer guidelines. The ELISA
showed that the distribution of positive and negative results in the community controls
was equal, whereas few participants were negative in the household contact (19%) and
TB groups (6%) (Table 3.4). For further analysis only QFT negative CTRLs (n=5), QFT
positive HHCs (n=13) and QFT positive TB cases (n=16) were assessed.
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COMMUNITY CONTROLS HOUSEHOLD CONTACTS TB INDEX CASES
RESULT Ag[IU/mL]
Ag-NIL
[IU/mL] RESULT
Ag
[IU/mL]
Ag-NIL
[IU/mL] RESULT
Ag
[IU/mL]
Ag-NIL
[IU/mL]
001 POS 0.55 0.42 04 POS 0.57 0.35 01 POS 14.68 14.51
002 POS 3.75 3.55 05 POS 19.44 19.22 03 POS 12.53 12.37
003 NEG 0.51 -0.28 09 POS 16.81 16.16 04 POS 12.01 11.80
004 NEG 0.77 0.26 11 POS 0.87 16.81 05 POS 3.07 2.93
005 POS 1.93 1.76 12 POS 10.93 10.79 06 POS 0.75 0.62
007 POS 5.65 5.31 18 POS 7.06 6.87 07 POS 0.63 0.51
008 NEG 0.23 0.11 19 POS 2.72 0.61 08 POS 2.21 1.74
009 POS 17.91 17.77 20 NEG 0.27 0.12 12 POS 1.27 1.14
010 NEG 0.29 0.12 21 POS 11.40 11.26 13 POS 3.50 3.37
012 NEG 1.16 -0.80 23 POS 1.28 1.02 001 POS 13.61 13.41
26 POS 5.95 5.23 002 POS 4.25 3.79
29 POS 4.58 4.11 003 POS 2.92 2.59
30 POS 12.32 11.99 004 POS 6.44 6.11
31 NEG 0.15 0.01 007 NEG 0.56 0.24
32 NEG 0.14 0.00 008 POS 5.42 5.23
34 POS 0.56 0.42 009 POS 18.83 18.57
010 POS 2.30 9.43
Table 3.4: QuantiFERON results. IFN-γ secretion in QFT supernatant in CTRLs, HHCs and TBs using
QuantiFERON®-TB GOLD ELISA.
3.5 Correlation between QFT and Luminex
QFT results are measured in IU/mL. Those values were transformed into pg/mL by
multiplying with the factor 40. The correlation of IFN-γ secretion obtained by QFT ELISA
and Luminex were assessed (Figure 3.8). No correlation was seen in QFT negative
subjects as all levels approached zero. In QFT positive and TB subjects a good
correlation between QFT ELISA and Luminex (as part of a 27 plex kit) was observed (r
0.75-0.96; p 0.0020 and p <0.0001).
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Figure 3.8: Correlation between Luminex and QFT results. Linear regression curve between IFN-γ
expression using Luminex vs. QFT ELISA. r shows the Spearman rank correlation coefficient and p the p
value. A good correlation was observed in QFT positive and TB subjects.
3.6 Luminex results
Using the Biorad multiplex assay, 27 markers in QFT supernatant could be
assessed simultaneously. Breen et al. have shown that there is no major difference
between extrapolated and not extrapolated datasets (7). Extrapolated data is routinely
used in the analysis of Luminex data and reported as valid results by the accompanying
analysis software. Values that fell outside the acceptable ranges appeared as OOR or
were set to Zero. While most of the markers did not show any differences, five markers
(FGF basic, GM-CSF, MCP-1, MIP-1β and VEGF) showed differences between HHCs
and TB cases (Figure 3.9). The unstimulated levels (NIL) of GM-CSF and VEGF were
higher in TB compared to HHC and were down regulated after stimulating with ESAT-6
and CFP-10 (Ag). The expression of those two cytokines was lower in TB cases than in
HHCs when unstimulated background was subtracted from antigen-stimulated values.
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FGF basic and GM-CSF showed an antigen specific increase in TB cases while MCP-1
and MIP-1β showed decreases in TB cases compared to HHC. When subtracting the
unstimulated background from antigen-stimulated values, a decrease was seen in TB
compared to HHC for MCP-1, MIP-1β and VEGF (significant with p=0.0099).
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Figure 3.9: Luminex Results. Results of expression of analytes in QFT supernatant after 18h stimulation
with ESAT-6 and CFP-10 (Ag). This figure represents median levels and ranges of analytes which show
significant differences between HHCs and TB cases. The Kruskal-Wallis test was used to calculate the p
value between groups.
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3.7 Flow Cytometry
3.7.1 Phenotyping
In this section the pattern of peripheral blood cell populations in CTRLs, HHC and
TB cases was assessed. The unstimulated QFT whole blood cells were phenotypically
assessed, defining monocytes, B cells, CD4 and CD8 T cells, and TCRγδ expressing
CD4 and CD8 T cells. 100µL of QFT blood was incubated with the specific markers for
20min and analyzed on a FACSCanto II. First, single cells were defined using forward
scatter-height (FSC-H) versus forward scatter-area (FSC-A) (Figure 3.10). The
lymphocyte and monocyte population could be determined according to the size (FSC)
and granularity (SSC) of the cells. The lymphocyte population was subdivided into B
cells using anti-human CD19, CD4 and CD8 T cells using combination of anti human
CD3, CD4 and CD8, and TCRγδ expressing CD4 and CD8 T cells using combination of
anti human CD3, CD4, CD8 and TCRγδ. Monocytes were identified using anti human
CD14. The percentage of each population was determined and differences between the
groups were assessed using Man Whitney test in GraphPad Prism 5.
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Figure 3.10: Gating strategy for phenotyping. Single cells (A) were included using forward scatter-
height (FSC-H) versus forward scatter-area (FSC-A). Using forward scatter (FSC) versus side scatter
(SSC) the lymphocyte and monocyte population could be determined followed by identification of B-cells
(B); identification of CD3 T cells (C), which is further subdivided into CD4 and CD8 T cells (D);
identification of TCRγδ T cells (E), which is further subdivided into TCRγδ+ expressing CD4 and CD8 (F)
and TCRγδ- expressing CD4 and CD8 (G); identification of monocytes using CD14 (H).
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Figure 3.11: Phenotyping. QFT cells after 18h stimulation were phenotypically assessed using the gating
strategy above. The Mann Whitney test was used to calculate the p value between any two groups.
The percentage of γδ T cells was similar in HHCs and TB cases (Figure 3.11-A).
CTRLs showed a lower number of γδ expressing CD3 T cells. When subdividing γδ
expressing CD3 T cells further the CTRLs showed a significant higher number of γδ
expressing CD4 T cells (p=0.021-0.0187) and lower number of γδ CD8 T cells. While the
percentages of CD3 T cells were similar between the three groups, differences were
seen in CD4 and CD8 T cells (Figure 3.11-B). The CTRL group had higher numbers of
CD4 cells than the HHCs and TB cases and no difference was seen between the HHCs
and TB cases. The percentage of CD8 T cells was also different among the groups, and
lower in CTRLs compared to the other two groups. The percentage of CD8 T cells was
slightly higher in TB cases than HHCs, which could be due to the low number of
subjects. The percentage of B cells was lower in HHCs and TB cases compared to
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CTRLs (Figure 3.11-C). TB cases showed a significantly higher percentage of CD14
compared to CTRLs (p=0.0050) and HHCs (p=0.0006) (Figure 3.11-D).
3.7.2 Assessing polyfunctional T cells in QFT WBA
Harari et al. (36) have shown that TNF-α expressing CD4T cells discriminate
between latent infection and active disease when stimulating with ESAT-6 and CFP-10.
Using their strategy it was determined whether the QFT WBA could replicate this result.
Therefore the QFT blood was re-stimulated with PMA/ Ionomycin for another 4h in the
presence of Brefeldin A. PMA/ Ionomycin were used at low concentration (2ng/ mL and
200ng/ mL respectively) to activate the cells. Samples with and without restimulation
were run in parallel. ICS was performed and cells analyzed using a FACSCanto II.
Polyfunctional T cells were assessed using the gating strategy below (Figure 3.12). In
short, single cells and lymphocytes were identified by forward and side scatter. CD3 T
cells were determined and subdivided into CD4 and CD8 T cells. A Boolean gating
strategy was used to assess the cytokine pattern in CD4 and CD8 T cells. The
expression of IL-9 and CD40L was determined by gating on CD4 and CD8 T cells.
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Figure 3.12: Gating strategy for polyfunctional T cells. Single cells (A) were included using forward
scatter-height (FSC-H) versus forward scatter-area (FSC-A). Using forward scatter (FSC) versus side
scatter (SSC) the lymphocytes could be determined followed by identification of CD3 T cells (B), which is
further subdivided into CD4 and CD8 T cells (C). The Boolean gating strategy was used to assess the
cytokine patterns in CD4 and CD8 T cells. Further, IL-9 and CD40L expression was assessed in CD4 and
CD8 T cells.
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Figure 3.13: Median Cytokine expression in antigen stimulated CD4 T cells with and without
restimulation. QFT tubes were left without restimulation (open symbols) or were stimulated with PMA/
Ionomycin (solid symbols) for another 4h in the presence of BrefA.
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Overall the cytokine profiles were similar in samples with and without
PMA/Ionomycin stimulation. For instance, TB cases showed a higher cytokine response
than HHC in both restimulated and unstimulated samples. Significant differences were
seen between CTRL and TB (p=0.0261/ 0.0318) or CTRL and HHC (p=0.0244) only
after PMA/Ionomycin restimulation (Figure 3.13). The cytokine expression in CTRL,
which were all QFT negative, did not increase when restimulated with PMA/ Ionomycin
apart from TNF-α/ IL-2 double positive cells. It appears that only cells, which are already
activated by antigens, respond to PMA/ Ionomycin at this low concentration. PMA/
Ionomycin restimulation therefore increases cytokine production to a level where it
becomes more easily measureable without altering differences between groups.
The cytokine profile in CD4 T cells did not show significant differences between
HHCs and TB cases (Figure 3.14). Significant differences were only seen between
CTRLs and TB cases in the single-cytokine expressing cells, TNF-α (p=0.0261), or two-
cytokine expressing cells, IFN-γ/TNF-α (p=0.0318) after stimulation with ESAT-6/CFP-
10. Significant differences disappeared when subtracting the unstimulated background.
As observed in the Luminex assay some cytokines show a higher background. In the
QFT-WBA, CTRLs showed a higher IL-2 response in NIL than antigen stimulated tubes.
The percentage of TNF-α expressing CD4 T cells was increased in TB cases compared
to HHCs, although not significantly so, after Ag stimulation, but this difference
disappeared after subtraction of background. Figure 3.14 also shows that TB cases and
HHCs usually had a higher background cytokine production than CTRLs. TB cases
showed a slightly lower number of IFN-γ/TNF-α and IFN-γ/IL-2 expressing CD4 T cells
compared to HHCs.
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The cytokine profile in CD8 T cells did not show significant differences between
HHCs and TB cases (Figure 3.15). Significant differences were only seen between
CTRLs and TB cases in expressing the single cytokine TNF-α (p=0.0129). As observed
in CD4 T cells, those significant differences disappeared when subtracting the
unstimulated background. When subtracting the background a statistically not significant
increase of CD8 T cells expressing TNF-α or IL-2 is seen in TB cases compared to
HHCs.
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Figure 3.14: Polyfunctional CD4 T cells in QFT WBA. Cytokine profile of polyfunctional CD4 T cells on
the basis of IFN-γ, TNF-α and IL-2 production. Responses to M. tb specific Ag (solid box) and NIL (blank
box) values from CTRLs (black), HHCs (grey) and TB cases (red) are shown. The upper graph shows
cytokine profiles in NIL and Ag stimulated samples and the lower graph shows cytokine profiles in Ag
stimulated samples minus background. All possible combinations of cytokines are shown below the
graphs.
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Figure 3.15: Polyfunctional CD8 T cells in QFT-WBA. Cytokine profiles of polyfunctional CD4 T cells on
the basis of IFN-γ, TNF-α and IL-2 production. Responses to M. tb specific Ag (solid box) and NIL (blank
box) values from CTRLs (black), HHCs (grey) and TB cases (red) are shown. The upper graphs shows
cytokine profiles in NIL and Ag stimulated samples and lower graphs show cytokine profiles in Ag
stimulated samples minus background. All possible combinations of cytokines are shown below the
graphs.
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IL-9 was thought to be expressed by TH2 cells, but Veldhoen et al. (108) showed
that IL-9 producing T cells were distinct from TH1, TH2, Treg and TH17 cells. Whereas
IL-9 levels were not statistically different in the Luminex experiments, TB cases show a
significantly higher background than HHCs in CD4 T cells in the ICS experiments
(p=0.0289) (Figure 3.16). When subtracting the background from the Ag stimulated tube
the expression level of IL-9 expression in CD4 T cells was similar in TB cases and
HHCs. The percentage of IL-9 producing CD8 T cells was elevated in TB cases
compared to HHCs. Statistically significant differences were only seen between CTRLs
and TB cases in the Ag tube (p=0.0119) and the Ag minus NIL tube (p=0.0118). In
general CD8 T cells showed a higher expression of IL-9 than CD4 T cells.
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Figure 3.16: Median expression of IL-9 in CD4 and CD8 T cells. QFT blood was incubated for 22h in
the presence of Brefeldin A for the last 4h. The expression of IL-9 in CD4 and CD8 T cells was analyzed
using FlowJo 7.6.5 and GraphPad Prism 5.
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Soon after activation, T cells express CD40L (CD154) and its interaction with CD40
regulates the expression of co-stimulatory factors, which leads to activation of naïve T
cells. CD40L is not only restricted to T cells and B cells. It can also be expressed by
monocytes, dendritic cells, endothelial cells and other cells types (91). In this study I
looked at the expression of CD40L in T cells.
The expression of CD40L in antigen specific CD4 and CD8 T cells respectively
was significantly lower in TB cases (0.0020/ 0.0101) compared to HHCs. CTRLs and
HHCs show a similar CD40L expression on CD4 T cells, while TB cases and CTRLs
showed a similar pattern in CD8 T cells. The expression of CD40L in T cells was higher
on CD4 than CD8 T cells.
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Figure 3.17: Median expression of CD40L in CD4 and CD8 T cells. QFT blood was incubated for 22h
in the presence of Brefeldin A for the last 4h. The expression of CD40L in CD4 and CD8 T cells was
analyzed using FlowJo 7.6.5 and GraphPad Prism 5.
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3.7.3 Assessing polyfunctional T cells in QFT Lymphocyte Proliferation Assay
(QFT LPA)
The present study showed that TB cases expressed higher levels of TNF-α than
HHC in QFT-WBA. After six days of stimulation, the expression of TNF-α increased and
resulted in a higher expression in HHC than in TB cases (Figure 3.19 – A). In a next
step the proliferating T cells were assessed using the gating strategy below. In short,
single cells and lymphocytes were identified by forward and side scatter. CD3 T cells
were determined and subdivided into proliferating CD4 and CD8 T cells, using Ki-67 as
proliferation marker. A Boolean gating strategy was used to assess the cytokine pattern
in proliferating T cells. Differences between the groups were analyzed using Kruskal-
Wallis test.
Looking at proliferating CD4 T cells (Figure 3.19 – B), HHC were still expressing a
high level of TNF-α. While there was no difference in the expression level of TNF-α/ IL-2
between HHC and TB cases in CD4 T cells, a difference was seen in proliferating CD4 T
cells. HHCs showed a higher expression of TNF-α/ IL-2 than TB cases, but not
significant.
To analyze if the T cells were proliferating the NIL and Ag tube were compared for
each group. In each group the percentage of proliferating CD4 T cells increased when
stimulated with Ag. Significant differences were seen in HHC (p=0.0313) and TB cases
(p=0.0029).
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Figure 3.18: Gating strategy for proliferating T cells. Single cells (A) were included using forward
scatter-height (FSC-H) versus forward scatter-area (FSC-A). Using forward scatter (FSC) versus side
scatter (SSC) the lymphocytes could be determined followed by identification of CD3 T cells (B), which is
further subdivided into proliferating CD4 and CD8 T cells (C). The Boolean gating strategy was used to
assess the cytokine patterns in proliferating CD4 and CD8 T cells.
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Figure 3.19: Polyfunctional CD4 T cells in QFT LPA. Cytokine profile of polyfunctional CD4 T cells on
the basis of IFN-γ, TNF-α and IL-2 expression. Responses to M. tb specific Antigens minus background
from CTRLs (black), HHCs (grey) and TB cases (red) are shown. Upper graph shows cytokine profile in
CD4 T cells only, while the lower graph shows the cytokine profile in proliferating CD4 T cells. All possible
combinations of cytokines are shown below the graph.
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Figure 3.20: Percentage of proliferating CD4 T cells. Percentage of Ki-67 expressing CD4 T cells are
shown after 6 day stimulation of NIL and Ag. Differences were calculated using the Wilcoxon matched
pairs test.
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When you take stuff from one writer it's plagiarism;
but when you take it from many writers, it's research.
Wilson Mizner
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In this thesis, the development of a QFT-WBA was shown step by step. The
responses in the QFT-based assay were generally comparable to the WBA that is
routinely used for vaccine immunogenicity assays. Re-stimulation methods, including
duration of stimulation and antigens were optimized. The new QFT-WBA was put in
place to answer immunological questions. Flow cytometry was used to look at
multifunctional and proliferating T cells and to characterize certain immune cells while
multiplex cytokine arrays can be used to investigate secreted host markers.
An estimated one third of the world population is infected with M. tb (114), which
can lead to active disease, when not controlled by the immune system (29;30). The
cellular immunity mediates the protective immune response due to expression of diverse
cytokines (50), such as IFN-γ, TNF-α and IL-2 (31;43;55;111), and T cells, which lead to
activation or cytolytic activity of macrophages (46).
The aim of this study was to develop a multi-platform immune analysis assay using
the QFT IT assay system. In this thesis it was shown that the QFT IT can be used not
only for IFN- γ ELISA. Chegou et al. (12) have already shown that it is suitable for
multiplex cytokine array. This thesis added to this work by using the QFT cell pellet for
flow cytometry. One set of QFT tubes will result in both plasma and white blood cells
from unstimulated and Ag stimulated samples, using only 1mL blood each. The plasma
was used for IFN-γ ELISA and Luminex looking at one or multiple cytokines at a time,
while the cells can be used for flow cytometry to characterize specific cell types, assess
polyfunctional and proliferating T cells.
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The issue of PMA/Ionomycin restimulation after initial antigen stimulation may be
contentious as it induces antigen independent stimulation of cytokine. However, in the
present study I have shown that a low concentration of the restimulants does not
increase cytokine production in participants who are naïve to the MTB antigens but
merely amplify existing responses to such a degree that the responses become more
easily measurable. Differences between groups were not affected. However, future
studies will include larger numbers of participants to thoroughly evaluate if restimulation
with receptor independent stimulants introduces artifacts or aid the analysis.
Although it was shown that the QFT assay could be used in flow cytometry, the
study has some limitations. Firstly the numbers in the groups were small. There were
only 5 participants available for the QFT negative CTRL group, 13 in the QFT positive
HHC group and 16 in the TB group.
Another limitation is the kinetics of the cytokine production. One study had shown
that in flow cytometry, the expression of IFN-γ and IL-2 reach a peak at 8h, TNF-α
already after 2h, and declined thereafter. They also showed that the cytokine level
decreases in naïve cells and increases in memory cells (62), suggesting that naïve T
cells develop a memory type. Another study showed that the optimum time to detect
TNF-α and IFN-γ was after 8h and 16h respectively (4). The optimum incubation times
seem to vary between different laboratories. Therefore it is clear that further work is
needed to investigate the optimal incubation times for different cytokines as the current
work only provides a snap-shot of cell function. The kinetics of cytokine production was
also different in supernatants than in single cell measurements. The peak expression of
each cytokine was much later than in flow cytometry. Some cytokines such as IFN-γ, IL-
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2, TNF-α, IL-1β, IL-6 and IL-10 showed the highest expression after 48h, while other
cytokines (TNF- β and IL-12) showed an increase after that time (52). This may be due
to a steady accumulation of cytokines that are secreted into the medium.
All results in this study were obtained by stimulating blood from adults. Taking the
QFT-WBA forward, it has to be addressed in infants and children and in HIV infected
adults as these are the populations of special interest for vaccine studies and also
where the QFT assay has been shown to result in increased indeterminate results
(1;84).
Despite these limitations the new developed assay has several advantages. 6-12h
WBA assays have been developed which require a stimulation step in the absence of
Brefeldin A, followed by addition of this Golgi apparatus inhibitor to trap the markers
intracellularly. Depending on the total stimulation time Brefeldin A is usually added after
2-5h (35). Often laboratories have to deal with late sample arrival and delayed
processing, which results in late evening work. After the first incubation step, samples
often get transferred into a programmable water bath, which switches off after a given
time. Using the QFT tubes, samples can be processed in batches and tubes can be left
at room temperature until all samples have been collected for the day. Once all samples
have been received the tubes can be transferred into an incubator. There is no
statistically significant difference in mRNA expression levels between tubes which have
been incubated immediately or after a delay of 3h (6). Although the effect of different
pre-incubation times on single cell marker expression, including intracellular cytokine
production, has not been specifically measured in the present study the published
mRNA work suggests that synchronized starting times of the incubation step at 37°C
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would not affect the results. This will be confirmed in future studies. In the present study,
after the 18h incubation, plasma was frozen, and cells were harvested, re-stimulated for
another 4h in the presence of Brefeldin A, red blood cells were lysed, and white blood
cells cryopreserved. This workflow, which takes place 18 hours after the start of
incubation, can be completed in 6h and represents a user-friendly assay system.
Hanekom et al. (35) have shown that stimulated WBA cells can be stored in liquid
nitrogen for 12 months, with comparable results to baseline assessment. With the new
QFT-WBA limited resources are required, as it only needs an incubator without a
programmable water bath, further simplifying the assay.
We need to confirm that different pre-incubation times (as mentioned above) and
the absence of CO2 enriched incubation at 37°C, as is generally practiced for the
conventional QFT assay, do not affect single cell cytokine production. This would add
another big advantage to the new assay as the time window for delivery of samples from
remote field research sites to more advanced laboratories capable of processing for ICS
would increase dramatically.
Multiplex cytokine arrays on QFT supernatants were conducted in the present
study and the results are in concordance with many other studies that employed
different functional assays. The Luminex data suggest that unstimulated values (NIL)
and not only antigen stimulated values minus the background (Ag-NIL) show differences
between groups. It is at present unclear whether the unstimulated QFT values correlate
with serum levels and this needs to be assessed in future studies. The expression of
VEGF and GM-CSF was higher in unstimulated samples. After stimulation with ESAT-6,
Stellenbosch University http://scholar.sun.ac.za
CHAPTER FOUR DISCUSSION
80
CFP-10 and TB10.4 the production of these markers was downregulated. The same
was reported in a study from Chegou et al. (12).
FGF basicAg, GM-CSFNIL, VEGFNIL/(Ag-NIL), MIP-1βAg and MCP-1Ag/(Ag-NIL) showed
differences between QFT pos HHC and TB cases. Chegou et al. (12) reported
statistically significant increases of MIP-1β and VEGF in HHC compared to TB cases.
Overall the present study showed that TB cases express less cytokines/chemokines
than HHC. This may be due to immune suppression in active disease or due to
compartmentalization of antigen-specific effectors to the site of disease. Several studies
have shown that MCP-1 is higher expressed in TB cases than HHC (32;48;87), which is
contradictive to the present study, but results compared in higher expression of MCP-1
in TB cases compared to CTRLs.
Similarly, flow cytometric analysis of the new QFT-WBA is in concordance with
published studies. Monocytes are important during innate immune response and
circulate in the blood (69). As expected the number of monocytes is statistical significant
higher in TB cases compared to CTRLs and HHC, which had also been shown by
Veenstra et al. (107).
The expression of CD40L is associated with activation of T cells. This study
showed significantly higher expression of CD40L in HHC than TB which is contrary to
some studies which have reported a significantly higher expression of CD40L in
pulmonary TB patients (67) and with tuberculosis pleurisy (59). However, the present
results are in accordance with a study from Chegou et al. (12) in which a higher number
of CD40L was found in peripheral blood of HHC compared to TB cases.
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While Luminex analysis showed a higher expression of IL-9 in HHC, flow cytometry
data showed that IL-9 expressing CD8 T cells were increased in TB cases compared to
HHC, suggesting that cells other than T cells also express IL-9 which was measured by
Luminex. A study by Wu et al. (114) showed that PBMCs of TB cases stimulated with
ESAT-6 express higher level of IL-9 mRNA than LTBI and TST-, which compares with
the findings in the present study.
In this study differences in the expression of TNF-α between QFT-WBA and QFT
LPA (6-day assay) were shown. In the QFT-WBA, TB cases show an increased
expression of TNF-α, which correlates with published findings, in which high frequencies
of TNF-α were found in TB cases stimulated with ESAT-6 or CFP-10 (36). When
stimulating QFT whole blood for six days, the HHC showed high frequencies of TNF-α
compared to TB cases. Further investigation showed that proliferating CD4 T cells
express higher levels of TNF-α in HHC. A study from Sutherland et al. (100) showed
increase of TNF-α in TB cases compared to TST negative and TST positive people. The
discrepancy in these findings may be explained by the different assays used in these
studies as the Sutherland group employed Luminex in plasma. In their study the
measured cytokine levels were not only produced by T cells, but also macrophages
(111). The same was seen in the expression of IFN-γ/IL-2, where TB cases showed
higher expression in the short term assay, and lower expression after six days. A study
by Davids et al. (19) also showed differences between those two assays, suggesting an
in vitro expansion of T cells from effector T cells in the short term assay and proliferating
central memory T cells in the long term assay.
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Future studies and implications
The QFT-WBA could be used in vaccine immunogenicity studies to assess
memory T cell induction. Many studies used whole blood stimulated with M. tb specific
antigens, which are also part of the trial vaccine (2;93). In those studies, approximately
1mL of blood per condition is needed, and at least 3 conditions have to be assessed,
(unstimulated, positive control and the antigen of interest). For studies where ESAT-6,
CFP-10 or TB7.7 antigens were used in the vaccine, including modified M. tb-based
vaccines, the QFT assay can be used directly. For other vaccines, the antigen of interest
can be added to a separate NIL tube and stimulation can be done as in this study
described. When assessing short term and long term assays even more blood is
needed. The QFT-WBA would assess immune responses against immunodominant M.
tb antigens but only require 2.4-3mL of blood to measure a range of immune responses.
This blood volume is feasible in studies on neonates, where allowable blood volumes
are small (28;39). Processing of the QFT-WBA is simplified, requires less advanced
laboratory equipment or procedures and may allow longer time windows for transport of
stimulated samples from field sites to immunogenicity laboratories. The first part of the
assay, the QFT tubes with optimized antigenic formulations, is produced under Good
Manufacturing Practice (GMP) standards and represents a widely available and simple
testing procedure. Adaptations as performed in the present study may allow widespread
application in larger, including phase III, trials with comparability of results across
different studies. In addition, the assay may be useful for other TB-related biomarker
investigations, including TB treatment response evaluation and diagnostic studies.
Further studies are underway to optimize mRNA extraction for transcriptome analysis in
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200 μL of QFT whole blood in addition to the soluble marker and cell-specific phenotypic
and functional assessment.
Stellenbosch University http://scholar.sun.ac.za
Reference List
(1) Aabye MG, Ravn P, PrayGod G, Jeremiah K, Mugomela A, Jepsen M et al. The impact of HIV
infection and CD4 cell count on the performance of an interferon gamma release assay in
patients with pulmonary tuberculosis. PLoS One 2009; 4(1):e4220.
(2) Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, Abrahams D et al. The novel
tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in
adults. Am J Respir Crit Care Med 2010; 181(12):1407-1417.
(3) Alberts B, Johnson A, Lewis J. Helper T cells and Lymphocyte activation. Molecular Biology of the
Cell. 4th edition. 2002.
(4) Antas PR, Sales JS, Pereira KC, Oliveira EB, Cunha KS, Sarno EN et al. Patterns of intracellular
cytokines in CD4 and CD8 T cells from patients with mycobacterial infections. Braz J Med Biol Res
2004; 37(8):1119-1129.
(5) Bergamini A, Bolacchi F, Pesce CD, Carbone M, Cepparulo M, Demin F et al. Increased CD4 and
CCR5 Expression and Human Immunodeficiency Virus Type 1 Entry in CD40 Ligand-Stimulated
Macrophages. Journal of Infectious Diseases 2002; 185(11):1567-1577.
(6) Bibova I, Linhartova I, Stanek O, Rusnakova V, Kubista M, Suchanek M et al. Detection of immune
cell response to M. tuberculosisÇôspecific antigens by quantitative polymerase chain reaction.
Diagnostic Microbiology and Infectious Disease 2012; 72(1):68-78.
(7) Breen EC, Reynolds SM, Cox C, Jacobson LP, Magpantay L, Mulder CB et al. Multisite comparison
of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 2011; 18(8):1229-1242.
(8) Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di CP, Titone L et al. Multifunctional CD4(+) T
cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010;
40(8):2211-2220.
(9) Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S et al. A New Mechanism of
NK Cell Cytotoxicity Activation: The CD40ÇôCD40 Ligand Interaction. The Journal of
Experimental Medicine 1997; 185(12):2053-2060.
(10) Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with
diverse cytokine profiles. Nat Med 2005; 11(10):1113-1117.
(11) Checkley AM, McShane H. Tuberculosis vaccines: progress and challenges. Trends Pharmacol Sci
2011; 32(10):601-606.
(12) Chegou NN, Black GF, Kidd M, van Helden PD, Walzl G. Host markers in QuantiFERON
supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med
2009; 9:21.
Stellenbosch University http://scholar.sun.ac.za
85
(13) Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q et al. Reduced Th17 Response in Patients
with Tuberculosis Correlates with IL-6R Expression on CD4+ T Cells. Am J Respir Crit Care Med
2010; 181(7):734-742.
(14) Cho S, Mehra V, Thoma-Uszynski S, Stenger S, Serbina N, Mazzaccaro RJ et al. Antimicrobial
activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proceedings of the National
Academy of Sciences of the United States of America 2000; 97(22):12210-12215.
(15) Coleman DL, Chodakewitz JA, Bartiss AH, Mellors JW. Granulocyte-macrophage colony-
stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood
1988; 72(2):573-578.
(16) Collins DM, Wilson T, Campbell S, Buddle BM, Wards BJ, Hotter G et al. Production of avirulent
mutants of Mycobacterium bovis with vaccine properties by the use of illegitimate
recombination and screening of stationary-phase cultures. Microbiology 2002; 148(10):3019-
3027.
(17) Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of
tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLoS One 2008;
3(7):e2624.
(18) Dannenberg AM, Jr. Delayed-type hypersensitivity and cell-mediated immunity in the
pathogenesis of tuberculosis. Immunol Today 1991; 12(7):228-233.
(19) Davids V, Hanekom W, Gelderbloem SJ, Hawkridge A, Hussey G, Sheperd R et al. Dose-
dependent immune response to Mycobacterium bovis BCG vaccination in neonates. Clin Vaccine
Immunol 2007; 14(2):198-200.
(20) De Rosa SC. Vaccine applications of flow cytometry. Methods 2012; 57(3):383-391.
(21) de Waard JH, Robledo J. Conventional Diagnostic Methods. In: Palomino JC, Leão SC, Ritacco V,
editors. Tuberculosis 2007-From Basic Science to Patient Care. 2010.
(22) De CM, D'Elios MM, Zancuoghi G, Romagnani S, Del PG. Human Th1 and Th2 cells: functional
properties, regulation of development and role in autoimmunity. Autoimmunity 1994; 18(4):301-
308.
(23) Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from
bench to bedside. Respirology 2010; 15(3):433-450.
(24) Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption -- a review on
tuberculosis. Mem Inst Oswaldo Cruz 2006; 101(7):697-714.
(25) Dye C, Anthony D.Harries, Dermot Maher, S.Mehran Hosseini, Wilfred Nkhoma, Felix
M.Salaniponi. Tuberculosis. Disease and Mortality in Sub-Saharan Africa. 2nd ed. 2006.
(26) Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of
tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global
Surveillance and Monitoring Project. JAMA 1999; 282(7):677-686.
Stellenbosch University http://scholar.sun.ac.za
86
(27) Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012; 12(8):581-591.
(28) Flanagan KL, Burl S, Lohman-Payne BL, Plebanski M. The challenge of assessing infant vaccine
responses in resource-poor settings. Expert Rev Vaccines 2010; 9(6):665-674.
(29) Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis
(Edinb ) 2004; 84(1-2):93-101.
(30) Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93-129.
(31) Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ et al. Tumor necrosis factor-
alpha is required in the protective immune response against Mycobacterium tuberculosis in
mice. Immunity 1995; 2(6):561-572.
(32) Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E et al. Discriminating between
latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb) 2011;
91(3):250-256.
(33) Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T et al. CD40 ligand is functionally
expressed on human eosinophils. Eur J Immunol 1995; 25(3):863-865.
(34) Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H et al. Induction of human IgE
synthesis in B cells by mast cells and basophils. Nature 1993; 365(6444):340-343.
(35) Hanekom WA, Hughes J, Mavinkurve M, Mendillo M, Watkins M, Gamieldien H et al. Novel
application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell
frequency in field studies. J Immunol Methods 2004; 291(1-2):185-195.
(36) Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP et al. Dominant TNF-alpha+
Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection
and active disease. Nat Med 2011; 17(3):372-376.
(37) Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a
role for Toll-like receptors. Nat Rev Microbiol 2010; 8(4):296-307.
(38) Hernandez-Pando R, Chacon-Salinas R, Serafin-Lopez J, Estrada I. Immunology, Pathogenesis,
Virulence. In: Palomino JC, Leão SC, Ritacco V, editors. Tuberculosis 2007-From Basic Science to
Patient Care. 2010.
(39) Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health
Organ 2011; 89(1):46-53.
(40) Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review.
Tuberculosis (Edinb ) 2011; 91(6):497-509.
(41) Ito M, Kojiro N, Ikeda T, Ito T, Funada J, Kokubu T. Increased proportions of peripheral blood
gamma delta T cells in patients with pulmonary tuberculosis. CHEST Journal 1992; 102(1):195-
197.
Stellenbosch University http://scholar.sun.ac.za
87
(42) Janeway CAJ, Travers P, Walport M. T-cell receptor gene rearrangement. Immunobiology: The
Immune System in Health and Disease. 5th edition. 2001.
(43) Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R et al. HIV-1 Infection Impairs the
Bronchoalveolar T-Cell Response to Mycobacteria. Am J Respir Crit Care Med 2009;
180(12):1262-1270.
(44) Kaufmann SH. Immunity to intracellular microbial pathogens. Immunol Today 1995; 16(7):338-
342.
(45) Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol
2001; 1(1):20-30.
(46) Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum
Dis 2002; 61 Suppl 2:ii54-ii58.
(47) Kaufmann SH. Tuberculosis: back on the immunologists' agenda. Immunity 2006; 24(4):351-357.
(48) Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, Zajdowicz MJ et al. Multiple
cytokines are released when blood from patients with tuberculosis is stimulated with
Mycobacterium tuberculosis antigens. PLoS ONE 2011; 6(11):e26545.
(49) Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.
Altern Med Rev 2003; 8(3):223-246.
(50) Kinjo Y, Kawakami K, Uezu K, Yara S, Miyagi K, Koguchi Y et al. Contribution of IL-18 to Th1
Response and Host Defense Against Infection by Mycobacterium tuberculosis: A Comparative
Study with IL-12p40. J Immunol 2002; 169(1):323-329.
(51) Kobayashi K, Yoshida T. The Immunopathogenesis of Granulomatous Inflammation Induced by
Mycobacterium tuberculosis. Methods 1996; 9(2):204-214.
(52) Kum WWS, Cameron SB, Hung RWY, Kalyan S, Chow AW. Temporal Sequence and Kinetics of
Proinflammatory and Anti-Inflammatory Cytokine Secretion Induced by Toxic Shock Syndrome
Toxin 1 in Human Peripheral Blood Mononuclear Cells. Infect Immun 2001; 69(12):7544-7549.
(53) Lalezari JP, Beal JA, Ruane PJ, Cohen CJ, Jacobson EL, Sundin D et al. Low-dose daily
subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+
patients: a randomized controlled trial. HIV Clin Trials 2000; 1(3):1-15.
(54) Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P et al. Human cytolytic and
interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc
Natl Acad Sci U S A 1998; 95(1):270-275.
(55) Lalvani A, Millington KA. T Cells and Tuberculosis: Beyond Interferon-gamma. J Infect Dis 2008;
197(7):941-943.
(56) Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997;
51:311-340.
Stellenbosch University http://scholar.sun.ac.za
88
(57) Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a
new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol
2011; 6(9):1067-1082.
(58) Leão SC, Portaels F. History. In: Palomino JC, Leão SC, Ritacco V, editors. Tuberculosis 2007-From
Basic Science to Patient Care. 2007.
(59) Li L, Qiao D, Fu X, Lao S, Zhang X, Wu C. Identification of Mycobacterium tuberculosis-Specific
Th1, Th17 and Th22 Cells Using the Expression of CD40L in Tuberculous Pleurisy. PLoS ONE 2011;
6(5):e20165.
(60) Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007; 370(9604):2030-2043.
(61) Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR. Childhood Pulmonary Tuberculosis:
Old Wisdom and New Challenges. Am J Respir Crit Care Med 2006; 173(10):1078-1090.
(62) Mascher B, Schlenke P, Seyfarth M. Expression and kinetics of cytokines determined by
intracellular staining using flow cytometry. J Immunol Methods 1999; 223(1):115-121.
(63) Matthews W. Consumption among the Indians. Trans Am Climatol Assoc Meet 1887; 3:234-241.
(64) McCarthy OR. The key to the sanatoria. J R Soc Med 2001; 94(8):413-417.
(65) McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV. Boosting BCG with
MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis
(Edinb) 2005; 85(1-2):47-52.
(66) Meraviglia S, El Daker S, Dieli F, Martini F, Martino A. gamma/delta T cells cross-link innate and
adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011;
2011:587315.
(67) Mizusawa M, Kawamura M, Takamori M, Kashiyama T, Fujita A, Usuzawa M et al. Increased
synthesis of anti-tuberculous glycolipid immunoglobulin G (IgG) and IgA with cavity formation in
patients with pulmonary tuberculosis. Clin Vaccine Immunol 2008; 15(3):544-548.
(68) Montoro E, Rodriguez R. Global Burden of Tuberculosis. In: Palomino JC, Leão SC, Ritacco V,
editors. Tuberculosis 2007-From Basic Science to Patient Care. 2007.
(69) Morcillo N. Tuberculosis in Children. In: Palomino JC, Leão SC, Ritacco V, editors. Tuberculosis
2007-From Basic Science to Patient Care. 2007.
(70) Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T
cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J
Immunol 1986; 136(7):2348-2357.
(71) Murali-Krishna K, Ahmed R. Cutting Edge: Naive T Cells Masquerading as Memory Cells. J
Immunol 2000; 165(4):1733-1737.
Stellenbosch University http://scholar.sun.ac.za
89
(72) National Department of Health South Africa. National Tuberculosis Management Guidelines
2009.  2009.
Ref Type: Report
(73) Ottenhoff THM, Kaufmann SHE. Vaccines against Tuberculosis: Where Are We and Where Do We
Need to Go? PLoS Pathog 2012; 8(5):e1002607.
(74) Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent
tuberculosis infection: moving the research agenda forward. The Lancet Infectious Diseases
2007; 7(6):428-438.
(75) Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J
Immunol 1983; 131(4):1613-1615.
(76) Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Norsen JP, Clark EA. Functional CD40 ligand
expressed by human blood dendritic cells is up-regulated by CD40 ligation. J Immunol 1996;
157(10):4363-4370.
(77) Pompei L, Jang S, Zamlynny B, Ravikumar S, McBride A, Hickman SP et al. Disparity in IL-12
release in dendritic cells and macrophages in response to Mycobacterium tuberculosis is due to
use of distinct TLRs. J Immunol 2007; 178(8):5192-5199.
(78) Raby E, Moyo M, Devendra A, Banda J, De HP, Ayles H et al. The effects of HIV on the sensitivity
of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One
2008; 3(6):e2489.
(79) Radziewicz H, Uebelhoer L, Bengsch B, Grakoui A. Memory CD8+ T cell differentiation in viral
infection: a cell for all seasons. World J Gastroenterol 2007; 13(36):4848-4857.
(80) Reljic R, Clark SO, Williams A, Falero-Diaz G, Singh M, Challacombe S et al. Intranasal IFNgamma
extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung
infection. Clin Exp Immunol 2006; 143(3):467-473.
(81) Ribeiro-Rodrigues R, Resende Co T, Rojas R, Toossi Z, Dietze R, Boom WH et al. A role for
CD4+CD25+ T cells in regulation of the immune response during human tuberculosis. Clinical &
Experimental Immunology 2006; 144(1):25-34.
(82) Richeldi L. An Update on the Diagnosis of Tuberculosis Infection. Am J Respir Crit Care Med 2006;
174(7):736-742.
(83) Rieder HL. Tuberculosis among American Indians of the contiguous United States. Public Health
Rep 1989; 104(6):653-657.
(84) Rose MV, Kimaro G, Nissen TN, Kroidl I, Hoelscher M, Bygbjerg IC et al. QuantiFERON(R)-TB gold
in-tube performance for diagnosing active tuberculosis in children and adults in a high burden
setting. PLoS ONE 2012; 7(7):e37851.
(85) Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines 2011;
10(5):645-658.
Stellenbosch University http://scholar.sun.ac.za
90
(86) Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of
gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993; 151(5):2497-2510.
(87) Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P. IP-10, MCP-1, MCP-2,
MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole
blood based T-cell assay. BMC Res Notes 2009; 2:19.
(88) Sallusto F, Geginat J, Lanzavecchia A. Central Memory and Effector Memory T Cell Subsets:
Function, Generation, and Maintenance. Annual Review of Immunology 2004; 22(1):745-763.
(89) SCHLUGER NEIL, ROM WILL. The Host Immune Response to Tuberculosis. Am J Respir Crit Care
Med 1998; 157(3):679-691.
(90) Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T-cell help for cytotoxic T
lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393(6684):480-483.
(91) Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58(1):4-43.
(92) Schwander SK, Sada E, Torres M, Escobedo D, Sierra JG, Alt S et al. T lymphocytic and immature
macrophage alveolitis in active pulmonary tuberculosis. J Infect Dis 1996; 173(5):1267-1272.
(93) Scriba TJ, Tameris M, Mansoor N, Smit E, van der ML, Isaacs F et al. Modified vaccinia Ankara-
expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces
polyfunctional CD4+ T cells. Eur J Immunol 2010; 40(1):279-290.
(94) Sedgwick JD, Riminton DS, Cyster JG, K÷rner H. Tumor necrosis factor: a master-regulator of
leukocyte movement. Immunology Today 2000; 21(3):110-113.
(95) Senol G, Erer OF, Yalcin YA, Coskun M, Gunduz AT, Bicmen C et al. Humoral immune response
against 38-kDa and 16-kDa mycobacterial antigens in tuberculosis. Eur Respir J 2007; 29(1):143-
148.
(96) Singh M, Espitia C. Immunological Diagnosis. In: Palomino JC, Leão SC, Ritacco V, editors.
Tuberculosis 2007-From Basic Science to Patient Care. 2010.
(97) Soares A, Govender L, Hughes J, Mavakla W, de KM, Barnard C et al. Novel application of Ki67 to
quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods 2010; 362(1-2):43-50.
(98) Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP et al. Differential Effects of
Cytolytic T Cell Subsets on Intracellular Infection. Science 1997; 276(5319):1684-1687.
(99) Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-restricted Foxp3+
natural regulatory T cells are specific for microbial antigens. The Journal of Experimental
Medicine 2006; 203(3):777-788.
(100) Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MOC. Production of TNF-+¦, IL-12(p40) and
IL-17 Can Discriminate between Active TB Disease and Latent Infection in a West African Cohort.
PLoS ONE 2010; 5(8):e12365.
Stellenbosch University http://scholar.sun.ac.za
91
(101) Suzuki K, Lee WJ, Hashimoto T, Tanaka E, Murayama T, Amitani R et al. Recombinant
granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha
(TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium
complex. Clin Exp Immunol 1994; 98(1):169-173.
(102) Tripathi RP, Tewari N, Dwivedi N, Tiwari VK. Fighting tuberculosis: an old disease with new
challenges. Med Res Rev 2005; 25(1):93-131.
(103) Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses
of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol 2006;
44(8):2844-2850.
(104) Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J
Pathol 2006; 208(2):261-269.
(105) van Pinxteren LAH, Ravn P, Agger EM, Pollock J, Andersen P. Diagnosis of Tuberculosis Based on
the Two Specific Antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 2000; 7(2):155-160.
(106) van KC, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67(1):2-17.
(107) Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N et al. Changes in leucocyte and
lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T
cells in fast treatment responders. Clin Exp Immunol 2006; 145(2):252-260.
(108) Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J et al. Transforming
growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an
interleukin 9-producing subset. Nature Immunology 2008; 9(12).
(109) Wallgren A. The time-table of tuberculosis. Tubercle 1948; 29(11):245-251.
(110) Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M et al. Passive protection with
immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004;
111(3):328-333.
(111) Wong KC, Leong WM, Law HK, Ip KF, Lam JT, Yuen KY et al. Molecular characterization of clinical
isolates of Mycobacterium tuberculosis and their association with phenotypic virulence in
human macrophages. Clin Vaccine Immunol 2007; 14(10):1279-1284.
(112) World Health Organization. Weekly epidemiological record; No. 4, 2004, 79, 25–40.  23-1-2004.
Ref Type: Report
(113) World Health Organization.Global Tuberculosis Control 2008; SURVEILLANCE
PLANNING FINANCING.  2008.
Ref Type: Report
(114) World Health Organization. Global Tuberculosis Report.  2012.
Ref Type: Report
Stellenbosch University http://scholar.sun.ac.za
92
(115) Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM et al. IL-9 is associated with
an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2008; 126(2):202-
210.
(116) Wu TC, Kurman RJ. Analysis of cytokine profiles in patients with human papillomavirus-
associated neoplasms. J Natl Cancer Inst 1997; 89(3):185-187.
(117) Zhang Y, Liu J, Wang Y, Xian Q, Shao L, Yang Z et al. Immunotherapy using IL-2 and GM-CSF is a
potential treatment for multidrug-resistant Mycobacterium tuberculosis. Sci China Life Sci 2012;
55(9):800-806.
Stellenbosch University http://scholar.sun.ac.za
